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The pentafluorosulfanyl (SF5) group is of increasing interest as a functional group in 
pharmaceutical and agrochemical research, and was recently labeled as the “substituent of the 
future”. It imparts unique properties to organic compounds and enhances their biological 
activities because of its high electronegativity, substantial steric effect, significant 
hydrophobicity and high chemical resistance.  To improve the activity and alleviate the 
neurotoxicity of the antimalarial drug mefloquine, we introduced the SF5 group into the 
quinoline methanolamine scaffold in place of the trifluoromethyl (CF3) group.  Three novel 
mefloquine analogs were synthesized in high yields from simple phenyl SF5 building blocks 
through short synthetic routes.  Two analogs were found to have improved activity and 
selectivity against malarial parasites, and one analog demonstrated lower membrane 
permeability, which is potentially advantageous for the reduction of the neurotoxic side effects.  
As part of this work, we also report the first SF5-containing quinoline heterocycles and the first 
ortho SF5 aniline.  
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1.0  INTRODUCTION TO MEFLOQUINE 
Malaria is an acute or chronic tropical mosquito-borne disease of man caused by the 
genus Plasmodium. The coccidian genus contains 172 species and four of them infect humans: 
Plasmodium falciparum, P. malariae, P. ovale and P. vivax. Only P. falciparum pose a 
substantial risk of death and are responsible for as many as 2.7 million casualties per year.1 The 
geographic extension of P. falciparum and its developing resistance to conventional antimalarial 
drugs have necessitated the development of new drugs that are active against resistant parasite 
strains and have good compliance.2 
Mefloquine is an orally-administered antimalarial drug used as a prophylaxis and 
treatment for malaria, especially against chloroquine-resistant parasite strains.3 However, its 
potential is limited due to its adverse central nervous system (CNS) effects, which include 
anxiety, depression, hallucinations and seizures.4 Despite the relatively high incidence of side 
effects, mefloquine continues to be used due to its long half-life, relative safety in pregnancy, 
activity against resistant strains, and the absence of effective alternatives. In order to ameliorate 
the neurotoxity profile of mefloquine, we set out to develop analogs that are less readily 
absorbed through the blood-brain barrier while still retaining the antimalarial activity. 
The chemistry of compounds that have a pentafluorosulfanyl (SF5) substituent is 
currently experiencing a renaissance, after their initial synthesis and characterization more than 
half a century ago.5,6  This novel functional group imparts unique properties to organic 
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compounds and enhances their biological activities because of its high electronegativity, 
substantial steric effect, significant hydrophobicity, and high chemical resistance.  
This document summarizes studies on the synthesis of three mefloquine analogs 
containing pentafluorosulfanyl (SF5) group as a replacement for the trifluoromethyl (CF3) group. 
Biological assays determined that the new analogs have equivalent or improved activities against 
P. falciparum parasites. Additionally, the 8-SF5 analog exhibits lower membrane permeability in 
an MDCK cell line screen, thus potentially reducing the adverse CNS effects of the parent 
antimalarial agent. 
1.1 TRANSMISSION OF MALARIA 
Malaria remains one of the world’s most important parasitic diseases with approximately 
300 million clinical cases and as many as 2.7 million of deaths per year. The female anopheles 
mosquito causes the transmission of malaria in man. And the human body is a host for 
mosquitoes, where sexual recombination can occur.  
1.1.1 Life cycle of causative plasmodia 
The essential features of the life cycle of the causative plasmodia are illustrated in Figure 
1.7 This cycle is divided into the sexual and asexual phases, with the sexual phase taking place in 
the female mosquito and the asexual phase taking place in man. When a human is infected 
through the salivary gland of the anopheles mosquito, sporozoites (fertilized zygotes) move 
rapidly away from the site of injection and enter liver cells in 30-60 min. They remain within the 
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hepatocytes for 9-16 days and undergo an asexual replication known as exo-erythrocytic 
schizogony. Each sporozoite gives rise to tens of thousands of merozoites inside the hepatocytes, 
which are released to the circulatory system following a rupture of the host hepatocytes.  
The merozoite recognizes specific proteins on the surface of the erythrocyte (a red blood 
cell, RBC) and actively invades the cell. The parasite starts a trophic period followed by an 
asexual replication. Trophozoite enlargement is accompanied by a highly active metabolism, 
which includes the ingestion of host cell cytoplasm and the proteolysis of haemoglobin into 
amino acids. The heme byproduct cannot be digested and polymerizes into the hemozoin 
(malaria pigment). After multiple rounds of nuclear division without cytokinesis, schizonts are 
formed and each mature schizont gives rise to about 12-16 merozoites. These merozoites are 
released through the ruptured schizont to invade further uninfected RBCs. This release coincides 
with a sharp increase in body temperature and is responsible for the characteristic clinical 
manifestations observed in a malaria attack. 
  In the erythrocytic stage, a small portion of the merozoites in the RBCs is differentiated 
to produce male and female gametocytes. When an infected individual is bitten by a subsequent 
female anopheles mosquito, these gametocytes are taken up by the mosquito and undergo 
gametogenesis to form male and female gametes. These gametes fuse, undergo fertilization and 
form a zygote. The zygote develops to form an ookinete, which penetrates the wall of a cell in 
the midgut and forms an oocyst. The oocyst matures, undergoes several nuclear divisions, and 
finally ruptures to release hundreds of sporozoites. These sporozoites migrate to the salivary 
glands and thereafter the mosquito remains infective. The life cycle of plasmodium is completed. 
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Figure 1 Life cycle of the plasmodium causing malaria (reproduced from Ref. 7) 
1.1.2 Clinical manifestation 
The clinical manifestation of a malaria attack is caused by the asexual erythrocytic 
schizogony in the blood. The rupture of RBCs by merozoites reduces the number of circulatory 
RBC, which results in low blood haemoglobin levels and causes the acute fever associated with 
malarial illness.8 Lowered haemoglobin levels contribute to anorexia in severe cases. In endemic 
areas, malaria often presents with other manifestations, such as pain in the joints, watery 
diarrhea, vomiting and convulsions.9 In some cases, secondary infections such as pneumonia or 
urinary tract infection can add to the difficulty of diagnosis.  
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1.1.3 Prevention and control of malaria 
Currently, no effective malaria vaccines are available. In endemic areas, prevention 
involves keeping mosquitoes away from humans and using prophylactic drugs to impede the 
malaria occurrence. The vector control measures include the use of insecticides to kill the 
mosquitoes and their eggs and larvae. Other preventive actions involve use of nets, closing of 
door and windows and use of mosquito repellents. Chemoprophylaxis is the use of medicine to 
prevent the infection in the human body. Man plays the major role in malaria control, and taking 
medicines is essential for people in areas where malaria is endemic.  
1.2 ANTIMALARIAL DRUGS 
An antimalarial drug is a drug used either to prevent or to cure malaria. The oldest and 
most famous drug is quinine, but there are many others on the market, such as chloroquine, 
sulfadoxine-pyrimethamine, mefloquine, proguanil, and artemesinin and its derivatives (Figure 
2).  
1.2.1 Quinine 
The history of quinine dates back to the 17th century in Peru when Jesuit priests learned 
from the Incas that powder from the cinchona tree bark relieved the shivering induced by the 
cold and the chills from malaria.10 Currently, it serves as a malaria treatment, but not for 
prophylaxis. It acts as a blood schizonticidal and weak gametocide during the asexual stage of 
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the parasite life cycle and it also inhibits the hemozoin biocrystallization to facilitate an 
aggregation of cytotoxic heme.11 Oral quinine is used to treat uncomplicated malaria in areas 
where there is known to be a high level of resistance to chloroquine, mefloquine and sulfa drug 
combinations with pyrimethamine.  
The use of quinine causes a syndrome known as cinchonism, which has adverse effects 
including primarily tinnitus, nausea and vertigo. Cardiovascular toxic effects are experienced in 
some cases because the drug is capable of prolonging the QT interval and the drug also has 
neurotoxic properties.12 A synthetic route toward quinine was described by Woodward and 
Doering in 1944,13 but this route is too complicated for commercial production. The perceived 
side effects along with the synthetic difficulty provided the impetus for scientists to develop 
synthetic alternatives. 
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Figure 2 The Structures of the main antimalarial drugs 
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1.2.2 Chloroquine  
Chloroquine was developed by scientists at the Bayer laboratories in Germany14 and 
patented as an antimalarial drug in 1946. It has been used for the treatment of malaria since the 
1960s. Its popularity over two decades has been due to its high efficacy, easy administration and 
good tolerability when used in the prescribed doses. Chloroquine is believed to reach high 
concentrations in the vacuoles of the parasite and raise the internal pH. It inhibits the 
biocystallization of hemozoin, causing the toxic heme to accumulate in the parasite and 
consequently poisons it through excess levels of toxicity.15  
 Chloroquine resistance in P. falciparum occurred in the late 1950s in Thailand and 
Columbia. Shortly afterwards, chloroquine resistance reached all regions of the world except 
Central America and some regions of Southwest Asia. It is now often used in combination with 
other antimalarial drugs to extend its effective usage.   
1.2.3 Sulfadoxine-Pyrimethamine  
The sulfadoxine-pyrimethamine combination is mainly used for treating P. falciparum 
infections and is less active against other Plasmodium strains. It is the standard second-line 
therapy against chloroquine-resistant falciparum malaria.16 This combination acts on the 
schizonts during the hepatic and erythrocytic phases and synergistically against folate synthesis, 
inhibiting dihydropteroate synthase and dihydrofolate reductase in the parasite.17 Since severe 
idiosyncratic skin allergies have been observed, this combination is not recommended for 
chemoprophylaxis yet; it is used frequently for clinical episodes of the disease. Resistance was 
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first recognized at the Thai-Cambodian border in the 1960s and has spread in sub-Saharan Africa 
and eastern Africa.18  
1.2.4 Mefloquine 
Due to problems in Vietnam with chloroquine-resistant malaria, the Walter Reed Army 
Institute for Research started a large-scale screening of potential antimalarial drugs, and 
mefloquine was synthesized and demonstrated to have potent activity against both P. falciparum 
and P. Vivax.19 Roche Pharmaceuticals is the major commercial manufacturer and markets the 
drug under the trade name “Lariam”. Mefloquine is effective for prophylaxis and for acute 
therapy and it is currently strictly used for resistant strains. Until recently, it was the drug of 
choice for U.S. military deployments in regions where malaria is endemic, primarily because of 
its long half-life, which allows weekly administration. However, associations of mefloquine with 
adverse neuropsychiatric effects, namely anxiety disorders, hallucinations, sleep disturbances 
and delirium, have curtailed its use.4 Mefloquine can only be taken for up to 6 months due to 
those side effects and subsequently, alternative drugs need to be taken.  
1.2.5 Proguanil 
Proguanil is a synthetic derivative of pyrimidine and was developed in the 1940s by a 
British antimalarial research group (Figure 2).20 It inhibits the malarial dihydrofolate reductase 
enzyme on the primary tissue stages of P. falciparum, P. vivax and P. ovale.21 When combined 
with atovaquone or chloroquine (in areas where there is no chloroguine resistance), it is useful in 
prophylaxis due to fewer side effects, which include slight hair loss and mouth ulcers.22 Thus, 
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proguanil is considered safe during pregnancy and breastfeeding, but insufficient drug is 
excreted in the milk to protect a breastfed infant.23 
1.2.6 Artemisinin and its derivatives 
Artemesinin is a Chinese herb (Qinghongsu) that has been used in the treatment of fevers 
for over 1,000 years. In 1985, the Journal of Traditional Chinese Medicine described its 
satisfactory efficacy in 100 patients, and artemisinin derivatives were soon thereafter recognized 
as having powerful antimalarial activity.24 Although the target within the parasite remains 
controversial, the derivatives have been shown to have potent activity against early trophozoite 
forms and to reduce rapidly heavy parasite infections.25 Now, it is strictly controlled under WHO 
guidelines because it has proven effective against all forms of multi-drug resistant P. falciparum, 
thus great care is taken to prevent resistance from developing. It is only given in combination 
with other antimalarials, such as mefloquine, in terms of parasite clearance.26 The most 
commonly reported adverse effects are mild abdominal pain, anorexia, nausea, diarrhea and CNS 
involvement,27 thus this antimalarial agent shows a favorable safety profile for the treatment of 
acute, uncomplicated P. falciparum malaria. 
1.2.7 Trends in antimalarial treatments 
   The major problem in the use of conventional antimalarial drugs is parasite resistance, 
especially against chloroquine.28 Development of new drugs, combination of two or more drugs 
and development of vaccines are the three main trends in the control of malaria. The new drugs, 
like dihydroartemisinine, artesunate and artemether (Figure 2), have a different mechanism of 
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action towards the parasite, which explains their rapid effects as well as their efficacy against 
drug-resistant malarial strains.29 The combination drugs, including artesunate/mefloquine, have 
been shown to be highly active against multidrug resistant P. falciparum infections. This 
combination may have played a role in both slowing down the development of resistance to 
mefloquine as well as reducing malaria transmission.30 Since vaccines based on a single antigen 
have a limited role in malaria due to the fact that not all people respond to the same antigen, 
development of multi-stage, multi-epitope, multi-component vaccines is undergoing.31 The use 
of antimalarial vaccine is currently in clinical trials and holds a great promise for antimalarial 
therapy.    
1.3 MEFLOQUINE 
There has been a growing public unease toward mefloquine, due to its severe 
neuropsychiatric effects, which were first publicized by a BBC Watchdog television program 
that appeared in the early 1990s. However, mefoquine is still the only weekly-administered drug 
that is efficacious against chloroquine-resistant P. falciparum malaria; therefore, mefloquine has 
a very important place in malaria treatment.  
1.3.1 Mechanism of action 
Like the structurally related chloroquine, mefloquine acts primarily on the erythrocytic 
asexual stages of the parasite (Figure 2). An early study of the ultrastructural changes induced by 
mefloquine in mice infected with P. falciparum, showed that the parasites’ food vacuoles 
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swelled with gradual loss of pigment granules when treated with mefloquine, indicating that the 
parasites’ food vacuoles are the drug target.32 However, mefloquine was shown to have relatively 
weak interactions with heme33 and too low of a basicity to change the pH in the food vacuole, 
making it unlikely that mefloquine would reach the intravacuolar concentration required to 
inhibit heme polymerization. Furthermore, a late study showed that mefloquine had no effect on 
hemozoin production of P. berghei infected mice.11 When a photoaffinity-labeling technique was 
used to identify mefloquine-binding proteins, two proteins with apparent molecular masses of 22 
and 36 kDa were found in three different strains of P. falciparum. They may be involved in the 
uptake of mefloquine or may represent macromolecular targets of mefloquine action in the 
parasites.34 The identities of these two polypeptides have not yet been established, and the 
detailed mechanism of action of mefloquine is still unclear. 
1.3.2 Adverse effects   
Mefloquine’s neuropsychiatric adverse effects range from anxiety and paranoia to 
depression, hallucinations and suicide.35 The incidence of adverse neuropsychiatric effects in 
malarial treatment users is 1:215 and 1:13,000 for chemoprophylactic users.36 One explanation 
for these undesirable events is the ability of mefloquine to interact and modulate the function of 
human P-glycoprotein.37 P-glycoprotein is thought to have a physiological role in regulating the 
entry of certain molecules into the central nervous system, especially as a detoxifier at the blood-
brain barrier.38 One recent study in 89 healthy white travelers showed that neuropsychiatric 
adverse effects of mefloquine are associated with polymorphisms in the MDR1/ABCB1 gene 
that encodes the efflux pump P-glycoprotein in women.39 The inhibitory effect of mefloquine on 
human P-glycoprotein could allow the drug to cross the blood-brain barrier and accumulate in 
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the central nervous system to exert the neurotoxic effect. Despite the relatively high frequency of 
adverse effects compared with other antimalarial drugs, mefloquine continues to be used due to 
the absence of effective alternatives. In order to ameliorate the neurotoxicity profile of the drug, 
we set out to develop analogs that are less readily absorbed through the blood-brain barrier but 
retain the antimalarial efficacy of the 4-quinolinecarbinolamine scaffold. 
1.3.3 Miscellaneous  
To aid in the efficient design of the 4-quinolinecarbinolamine antimalarial drugs, a 
detailed computational study on a series of compounds in this class was performed using the 
semiempirical Austin model 1 (AM1) to correlate the electronic features with the antimalarial 
activity.40 This investigation shows that the large, broad, laterally extended negative potential 
region adjacent to the quinoline ring would be expected to increase the lipophilicity of the 
molecule because of high electron density and consequent hydrophobicity in the region. In order 
to modulate the electron density, electron-withdrawing groups such as CF3, F or Cl should be 
placed at both the 2- and 8- positions of the quinoline ring. Our first strategy for generating new 
analogs was the replacment of the CF3 group with another highly electron withdrawing group. 
Aside from electronic properties, the stereochemistry of mefloquine plays an important 
role in its biological activities. The enantiomer (+)-(11R,2’S)-mefloquine showed a significantly 
lower incident of side effects in comparison to the (-)-enantiomer in a study of the behavioral 
effects in mice dosed daily with the two enantiomers.41 This study also demonstrated that the (-)-
enantiomer is a selective ligand for the adenosine A2A receptor subtype in vitro, whereas the 
binding of the (+)-enantiomer is over two orders of magnitude weaker. These data lead to the 
conclusion that treating or preventing malaria with the (+)-enantiomer of mefloquine may be 
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effective in reducing the side effects. This result prompted us to separate the two enantiomers 
and test the efficacy of (+)-enantiomers separately.  
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2.0  INTRODUCTION OF THE PENTAFLUOROSULFANYL GROUP 
The pentafluorosulfanyl (SF5) group is an organic derivative of the hypervalent molecule 
sulfur hexafluoride (SF6). Due to its kinetic stability, SF6 is not a useful reagent in chemical 
reactions; nucleophilic attack on SF6 has a high activation energy due to steric hindrance. 
Therefore, the SF5 group is an important derivative for investigating the special features of these 
hypervalent moieties. The total number of well-characterized R-SF5 compounds is already quite 
large, but there are only limited and difficult routes for the preparation of this special functional 
group.  
2.1 PHYSICAL CHEMISTRY OF ORGANIC SF5 COMPOUNDS 
The SF5 group has special properties due to its octahedral geometry and five electron-
withdrawing fluorine atoms. Its properties can be compared with the CF3 group, which is a 
common functional group in biologically active compounds.  
2.1.1 X-ray structure 
The structure of the SF5 group is characteristic of the octahedral environment around 
sulfur, as shown in the X-ray structure of 3-(pentafluorosulfanyl)benzoic acid (Figure 3).42 The 
 15 
sixth coordination site for the center sulfur atom is occupied by the phenyl carbon with the 
equatorial fluorine atoms staggered to the flat benzene moiety to be energetically favorable. The 
bond length of the S-Fax bond (1.587(3) Å) is slightly longer than that of the S-Feq bond 
(1.561(4) Å), and the C-S bond distance is 1.804(2) Å. Both bond angles of Fax-S-Feq (87.6(3)˚, 
average) and Feq-S-Feq (90.9(3)˚, average) are comparable to those of other SF5 analogs, and all 
of them are close to 90˚.43  
 
Figure 3 X-ray structure of 3-(pentafluorosulfanyl)benzoic acid 
2.1.2 Steric hindrance 
 The rigidity of the bonds within the SF5 group is characteristic of a bulky group. The S-
C-S bond angle in F5S-CH2-SF5 is 126.1(8)˚ while the central C-C-C angle in di-t-butylmethane 
is 128˚.44 For comparison, F3C-CFI-CF3 has a C-C-C angle of 113.2˚ , which is smaller than the 
two angles above, but the influence of the large iodine atom should be considered.45 The relative 
steric demand of the SF5 group is similar to that of a tert-butyl group and therefore significantly 
greater than that of a CF3 group. 
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2.1.3 Electronic properties  
 The electronegativity of the SF5 group has been proposed to be as high as 3.65, vs 3.36 
for the CF3 group, according to the effects of the substituent on the carbon 1s ionization energies 
and the acidities of trifluoropropyne (CF3C≡CH) and ethynylsulfur pentafluoride (SF5C≡CH).46 
These data show that the electronegativity of SF5 and CF3 groups lies between fluorine and 
chlorine. In another study, the electronic effects of SF5 and CF3 groups on aniline are calculated 
by ab inito molecular orbital methods.43 The electrostatic potential (ESP) surfaces in Table 1 
demonstrate that the SF5 group is more electron-withdrawing than the CF3 group. The 
electrostatic potential on nitrogen is diminished considerably in SF5-anilines 2a and 2b, and the 
molecular dipole increases upon exchange of a CF3 group for an SF5 group.  
Table 1 Calculated (HF/6-31G(d)) properties of SF5-anilines and the corresponding CF3-anilines 
SF5
NH2
CF3
NH2
F5S
NH2
F3C
NH2
structure
ESPmin (NH2)a
Dipole (D)
-11.1
5.22
-33.8
3.70
-8.23
6.27
-12.5
4.87
2b 3b 2a 3a
 
a Minimum value (in kcal) of the electrostatic potential surface centered on the nitrogen atom of the amino group 
2.1.4 Chemical stability 
Due to the strength (D0°(F4S-F) = 53.1 ± 6.0 kcal/mol)47 and rigidity of the S-F bond, the 
SF5 group is considered stable under a variety of chemical conditions. In the first paper reporting 
the synthesis of aryl sulfur pentafluoride, the stability of phenylsulfur pentafluoride (Ph-SF5) was 
investigated.48 When the compound was subjected to a 1.0 N NaOH solution at 94 °C for 4 h, no 
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fluoride ion was detected. In sulfuric acid (98 - 100%), the compound started to decompose to 
form benzenesulfonyl fluoride only after the temperature went up to 100 °C. In a control 
hydrolysis of benzotrifluoride (Ph-CF3) under the same acidic conditions, it was found that the 
benzotrifluoride was hydrolyzed at 90 °C in less than 5 min. 
Another recent study of hydrolysis of SF5-anilines also demonstrated that the SF5 group 
exhibits higher chemical resistance than the CF3 group. The study indicated that in a 2.0 N NaOH 
solution at room temerature, 4-CF3-aniline 3a readily hydrolyzed whereas 4-SF5-aniline 2a was 
recovered in high yield (91%).43 
2.2 PREPARATION OF PENTAFLUOROSULFANYL COMPOUNDS 
Despite their origins dating back half a century, only a limited number of 
pentafluorosulfanyl compounds have been prepared, mainly due to the difficulty of preparation 
and the small amount of commercially available SF5 building blocks. 
2.2.1 First organic SF5 derivative 
The first organic SF5 compound was an unexpected product in the attempted preparation 
of trifluoromethyl mercaptan (CF3SF5) (eq 1). Under the harsh conditions with cobalt trifluoride 
at more than 200 °C, the novel trifluoromethylsulfur pentafluoride (CF3SF5) was detected in 20% 
yield (eq 1).5 The attractive properties of this novel substituent, such as its chemical inertness 
and its electron demand, sparked an interest for further study.  
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CH3SH CF3SF5 + CF4 + CHF3 +SF6
CoF3, Cu
20%250 - 275 °C
(1)
 
2.2.2 Preparation of aliphatic SF5 compounds 
The oldest and most common way to add the SF5 group to an aliphatic chain is vigorous 
fluorination of a sulfur-containing precursor. When pentafluorosulfanyl chloride (SF5Cl) became 
more readily available, it turned into the main reagent for incorporation of the SF5 group and has 
been used since the 1960s. Recently, a growing number of chemical companies have started to 
sell SF5 building blocks, and using commercially available materials has become more feasible.  
2.2.2.1 Vigorous fluorination 
Vigorous fluorination was the first reported method to generate the SF5 group. It requires 
the harsh conditions, resulting in many side products and low yields. The common conditions are 
the use of hydrogen fluoride with a Simons Cell (eq 2) and elemental fluorine in nitrogen (eq 3). 
In these environments, the sulfur atom on the substrate undergoes the maximum fluorination and 
forms the stable SF5 group.49, 50  
[(CH3CH2)NCH2CH2S]2 (CF3CF2)NCF2CF2SF5
HF, Simons Cell
13%
SF3CN
F2/N2 (1:10)
-120 °C, 10% SF5CN
(2)
(3)
 
2.2.2.2 Radical reactions of SF5Cl and SF5Br 
Radical reactions of SF5Cl and SF5Br allow for the selective introduction of the SF5 
group at unsaturated carbons and generally result in much higher yields than vigorous 
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fluorination methods. Photochemical51 (eq 4), thermal52 (eq 5) and radical initiated53 (eq 6) 
additions are applied and specialized conditions are required for different substrates. 
F5S
OH
Cl
SF5Cl   +
hν, CFCl3
76%
C4H9
C4H9
Cl
F5S
Et3B, hexane
-30 °C to r.t.
98%
SF5Cl   +
SF5Cl   + H2C CHCH3 SF5CH2CHClCH3
90 °C, autoclave
78%
OH
(4)
(5)
(6)
 
2.2.3 Preparation of aromatic SF5 compounds 
To date, only a limited amount of aromatic pentafluorosulfanes have been prepared, 
although the first aromatic SF5 compound was synthesized more than half a century ago.48 
Oxidative fluorination of bis-nitrophenyl disulfide under harsh conditions is still the generally 
preferred procedure. All improved routes involve expensive silver difluoride or dangerous 
elemental fluorine, and there is still a considerable need for practical synthetic routes.  
2.2.3.1 First aromatic SF5 compounds 
The first aromatic SF5 compounds were reported by Sheppard in 1962 (eq 7 and 8) and 
their electrical effects were studied shortly after.48,54 The synthesis was accomplished by the 
reaction of bis-nitrophenyl disulfide with silver difluoride at 120 °C. The meta- and para-
nitrophenylsulfur pentafluorides were successfully prepared in low yields (eq 7 and 8). In 
contrast, the corresponding ortho-nitro product was not formed from the ortho-nitrophenyl 
disulfide, presumably due to the steric hindrance from the ortho-nitro group preventing further 
fluorination of the triflurosulfanyl (SF3) intermediate to give the SF5 moiety. 
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S S
O2N NO2
SF5
O2NAgF2, CFC-113a
120 °C, 30%
S S SF5
AgF2, CFC-113a
120 °C, 15%O2N NO2 O2N
(7)
(8)
 
a CFC-113: 1,1,2-trichloro-1,2,2-trifluoroethane 
2.2.3.2 Direct fluorination 
Recently, direct fluorination of bis-nitrophenyl disulfide by a mixture of F2 and N2 gas 
(1:9 v/v) in anhydrous acetonitrile was developed as a new method with higher yields and 
cheaper reagents (eq 9 and 10).43 This procedure has been successfully applied to the preparation 
of multi-kilogram quantities of m- and p-SF5-benzenes (eq 9 and 10), but it could not be applied 
to the ortho-substituted starting materials, which gave only the intermediate trifluorosulfanyl 
compounds as major products.  
S S
O2N NO2
SF5
O2NF2/N2 (1:9 v/v)
MeCN, -5 °C 
39%
S SO2N NO2
F2/N2 (1:9 v/v)
MeCN, -5 °C 
41%
(9)
(10)SF5O2N
 
2.2.3.3 Improved AgF2 fluorination to prepare the first ortho-SF5 arenes 
The only diphenyl disulfur substrate containing an ortho-substituent suitable for direct 
fluorination is the bis-ortho-fluorodiphenyl disulfide.55 This substrate was converted to the 
ortho-fluoro-SF5-benzene by AgF2 with copper at high temperature. Although the yield is low 
(18%), this route is the only reported example of fluorination of a disulfide bond to yield an SF5 
arene with an ortho-substituent (Scheme 1). The success on this substrate is due to the small size 
of the ortho-fluoride atom to avoid steric hindrance and the electron-withdrawing nitro group. 
Combinations of other functional groups gave no SF5-containing products. The fluoride 
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substituent can subsequently be converted to other functional groups, such as the amino group 
and the ethoxy group (Scheme 3). 
Scheme 1 First synthesis of the ortho-substituted SF5-benzenes 
S S
R2 R2
SF5
R2
AgF2, CFC-113a, Cu
125 °C, 18%
R1 R1 R1
No SF5 product
R1 = F; R2 = NO2
R1 = F; R2 = Br
R1 = Cl; R2 = NO2
R1 = Br; R2 = NO2
R1 = p-NO2-C6H4; R2 = NO2  
a CFC-113: 1,1,2-trichloro-1,2,2-trifluoroethane 
2.2.3.4 Transformations of SF5 arene building blocks 
There are a few commercially available m- and p-substituted SF5 aromatic building 
blocks, and their chemical inertness allows a variety of transformations, such as organometallic 
coupling43 (Scheme 2) and nucleophilic aromatic substitution reactions55 (Scheme 3).   
Scheme 2 Organometallic coupling of the SF5 aryl iodide 
F5S I
Ph
Sonogashira
75%
SF5
Ph
Suzuki
96%
Stille
76%
Ph
B(OH)2
Ph
Sn(Bu)2
SF5
Ph
Heck
65%OMe
O
F5S OMe
O
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Scheme 3 Nucleophilic aromatic substitution of the ortho-SF5 fluorobenzene 
F
SF5O2N
NaSMe, EtOH, reflux
45%
SMe
SF5O2N
NH4OH (28%), 135 °C
61%
NH2
SF5O2N
EtOH, KOH, reflux
49%
OEt
SF5O2N  
2.3 APPLICATIONS OF SF5 COMPOUNDS 
Because of the similar structure and electronic properties of the SF5 and CF3 groups, the 
novel SF5 substituent is often used as a CF3 replacement. Compounds containing an SF5 group 
have shown useful properties ranging from liquid crystals to pesticides to pharmaceutical agents. 
2.3.1 Liquid crystals 
Since the 1980s, the SF5 group has been the subject of preliminary investigations in some 
liquid crystal research groups due to its high polarity and stability. It’s the most polar terminal 
group that is compatible with active matrix technology and induces a high dielectric anisotropy 
(∆ε). Regarding the liquid crystals in Figure 4, the current limit for compatible materials is 
achieved with the trifluoromethyl group (4a, ∆ ε = 8.6). Unfortunately, the much more polar 
materials based on a terminal cyano group (4b, ∆ ε = 21.1, PCG-3) cannot be used since the 
cyano group tends to solvate ionic impurities, resulting in a low voltage holding ratio.56 To 
further increase the ∆ε of these materials, the quite polar SF5 group was introduced to replace the 
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CF3 group and a PM3 calculation on 4c gave a ∆ ε value of 22.2.56 This result predicted a 
considerable potential of the SF5 group as a structural component. In a later study, the SF5-
containing compound 5b showed a higher ∆ε (14.3) than its CF3 congener 5a (∆ε = 13.0).57  
C3H7
4a R = CF3 (∆ε = 8.6)
4b R = CN (∆ε = 21.1, PCG-3)
4c R = SF5 (∆ε = 22.2, PM3)
C3H7 RR
5a R = CF3 (∆ε = 13.0)
5b R = CN (∆ε = 14.3)
 
Figure 4 Dielectric anisotropies of liquid crystals with fluorinated and cyanated groups  
2.3.2 Pesticides 
Many pesticides contain CF3 groups, and the emergence of the SF5 group inspired the 
site-to-site replacement studies on these biologically active compounds. Trifluralin (2, 6-dinitro-
N,N-dipropyl-4-trifluoromethylaniline, 6a, Figure 5) is one of the top five herbicides produced in 
the US, and it was chosen as the parent compound to study the biological effects of the 
replacement of the CF3 group with the SF5 group. The SF5 analog 6b was synthesized from 
commercially available p-nitro-SF5-benzene, and it was found to be approximately twice as 
potent as trifluralin with the same general spectrum of activity. Furthermore, in pre-emergence 
tests, the herbicidal activity of 6b, in terms of crop injury and weed control, is nearly five fold 
greater than the parent agent 6a.58  
O2N NO2
CF3
N
O2N NO2
SF5
N
Trifluralin 6a 6b  
Figure 5 Trifluralin and its SF5 analog 
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2.3.3 Pharmaceutical agents 
The application of the SF5 group in pharmaceutical agents is slowly emerging, and there 
are a significant number of patents covering this topic. The investigation of inhibitors for 
sodium-proton exchanger (NHE) involves the synthesis of SF5-containing compounds. The first 
class of inhibitors include benzoylguanidine compound HOE 694 (7a), in which the guanidinium 
component mimics the sodium ion to block membrane transport (Figure 6). Further studies 
demonstrated that the activity might be enhanced by a lipophilic, bulky group at the 4-position of 
the benzene ring. Thus, the SF5 was installed in that position to arrive at analog 7b. The latter 
agent demonstrated improved bioavailability and half-life in vivo in comparison to other NHE 
inhibitors.59  
F5S
N NH2
NH2O
7b
N NH2
NH2O
7a
S
O
O
N
 
Figure 6 Benzoylguanidine NHE inhibitors 
 
 
    
 
 25 
3.0  RESULTS AND DISCUSSION 
In this study, we seek to modify the quinoline methanol scaffold with the SF5 functional 
group to yield derivatives that exhibit fewer adverse neurological effects while retaining their 
antimalarial efficacy.  
3.1 SYNTHESIS OF THE 6-SF5-QUINOLYL MEFLOQUINE ANALOG 
Because installation of the SF5 group demands harsh conditions and is low yielding, we 
began our study using commercially available SF5 building blocks. Presumably, one of the 
accessible aromatic building blocks, 4-SF5-aniline (2a), would be a suitable staring material for 
the 6-SF5-quinolyl mefloquine analog 8a (Figure 7).    
N
N
H
HO
CF3
NH2
8
7
6F5S
F5S
4-SF5-aniline (2a)6-SF5-quinolyl analog (8a)  
Figure 7 The starting material chosen for the synthesis of the 6-SF5 analog of mefloquine 
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3.1.1 Fluoride ion-catalyzed Wittig rearrangement route 
The first synthesis of mefloquine was published in 1971,60 and several other routes have 
been developed since then.61 At first, an expedient and high yielding synthesis of mefloquine via 
a fluoride ion-catalyzed Wittig-[1,2]-rearrangement was selected as the route to access 
compound 8a.62 This is the first example of a fluoride ion catalyzed Wittig rearrangement. This 
synthesis is summarized in Scheme 4. 
Scheme 4 Reported synthesis of mefloquine through fluoride ion catalyzed Wittig rearrangement  
N
CF3
OH
CF3N
Cl +
N
CF3
O
CF3
N
NaH, Toluene
DMF, 150 °C 
90%
•HCl
910 11
n-BuLi, TBSCl
-78 °C, THF
70% N
CF3
O
CF3
N
12
TBS
N
CF3
CF3
13, 45%
N
HO
N
CF3
CF3
14, 40%
N
O
+TBAF, MeCN
TBAF, MeCN, air, quant.
N
CF3
CF3
1 dr > 20:1
N
H
HO
PtO2, HCl, H2
MeOH, EtOH, 80%
 
Prior to the use of the SF5 substrate, we first attempted to reproduce these results. The 
hydroxyquinoline 9 was synthesized from 2-trifluoromethyl aniline (Table 2) through a Conrad-
Limpach reaction with ethyl 4,4,4-trifluoroacetoacetate in the presence of polyphosphoric acid. 
Although the yield was low (18%), the reaction afforded enough material to attempt the next step 
formation of aryl ether 11. The ratio of the two solvents toluene and DMF was not mentioned in 
the previous example so we explored the suitable conditions. Starting with a 1:1 ratio of 
DMF/toluene and changing it to 1:10 and neat toluene, all conditions gave no comparable yields 
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as in the paper. However, milder reaction conditions using KI as a catalyst with Na2CO3 in DMF 
were found to give aryl ether 11 in good yield (88%). 
Table 2 Conditions for the synthesis of aryl ether 11 
NH2
CF3
F3C OEt
O O
PPA, 150 °C, 18%
N
CF3
OH
CF3
15 9
N
Cl+
•HCl
10
N
CF3
O
CF3
N
11
entry solvent results
1
3
time (h)
18
3
9 + 11a
11 (88%)b
base (equiv) catalyst
1:1 (DMF/toluene) NaH (2.2)
Na2CO3 (3.8) KI (0.15 equiv)
none
2
4
8 11 (4%)btoluene NaH (3.2) none
15 11 (31%)b1:10 (DMF/toluene) NaH (2.7) none
conditions
DMF
Temp. (°C)
110
110
110
80
 
a TLC showed both 9 and 11 after 18 h. 
b These are isolated yields. 
The next step was the key fluoride ion-catalyzed rearrangement. The important features 
of the Wittig-[1,2]-rearrangement are: a) the substituent at the ether oxygen has to be able to 
stabilize the carbanion, b) yields are usually moderate due to the harsh reaction conditions and c) 
a [1,4]-pathway can compete.63 Based on the literature example, aryl ether 11 should be a 
suitable substrate for the conversion to arylcarbinol 13. However, the author mentioned that 
treatment with strong bases, such as phenyl lithium, n-butyl lithium or sodium amide at varying 
temperatures gave only decomposition and tar products.62 This result prompted the author to 
prepare a substrate that would lead to a more stabilized carbanion intermediate. The trialkylsilyl 
moiety acts as a protected carbanion64 that may be easily unmasked with catalytic amounts of 
fluoride ion, and introduction of a trialkyl silyl substituent onto 11 ought to facilitate the 
rearrangement. The substrate 11 was deprotonated with n-butyl lithium and then trapped by 
TBSCl to form compound 12. The TBS group was removed using TBAF in MeCN and the 
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resulting carbanion underwent the rearrangement smoothly to give the desired product 13 (45%) 
and its oxidized form 14 (40%).  
When we applied the reported conditions to form organosilicon compound 12, no desired 
product was detected. To investigate the feasibility of the deprotonation, the carbanion was 
trapped with deuterated methanol. According to the integrations of 1H NMR, when 1.1 equiv of 
s-BuLi was used, 20% of both protons on the methylene and 3-position methine (Figure 8) were 
exchanged with deuterium. 30% of the protons were exchanged while 2.0 equiv of base was 
used. Due to these results, the acidities of these two protons are similar. Thus, two equivalents of 
base are required for complete deprotonation on the methylene and subsequent formation of 
organosilicon compound 12. 
N
O
CF3
CF3
N
11
H
H
3
 
Figure 8 Deprotonation substrate 11 
We screened several bases in THF and toluene at -78 °C (Table 3).  Most of these 
conditions led to decomposition or recovered starting material. Only n-butyl lithium (3.0 equiv) 
in toluene (entry 8) provided a mixture of product and starting material. However, attempts to 
push the reaction to completion through increasing the equivalents of base resulted in 
decomposition and gave complex mixtures.   
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Table 3 Conditions screened for preparation of Wittig rearrangement precursor 
N
O
CF3
CF3
N
N
O
CF3
CF3
N
base, TBSCl
-78 °C to rt
TBS
11
entry
1
2
3
4
base (equiv) resultsa
s-BuLi (2.0)
dec.
11 (64%)
solvent
THF
THF
12
LDA (2.0) THF 11 (13%)
n-BuLi (2.0)
n-BuLi (3.0)
toluene
toluene
n-BuLi (4.0) toluene
11 (30%)
12 (21%) and 11 (25%)
dec.
t-BuOK/n-BuLi (2.0)
LiNEt2 (2.0)
LiHMDS (2.0)
THF
THF
THF
dec.
dec.5
6
7
8
9
dec.
n-BuLi (2.0)
 
a The starting material and product are isolated after reaction.  
Direct Wittig-[1,2]-rearrangement to give product 14 was observed when TMEDA was 
used to increase the reactivity of n-butyl lithium (eq 11).65 This observation was made on a 
reaction scale of 15 mg, and the product was identified as the ketone 14 from the oxidation of the 
alcohol precursor 13.  
N
O
CF3
CF3
N
N
CF3
CF3
N
O
2.0 equiv n-BuLi, TMEDA
THF, -78 °C to rt
11 14
(11)
 
Inspired by this observation, we carried out an optimization of the base, additive, and 
solvent, and selected conditions are listed in Table 4. The best results were obtained using 
LiTMP (1.0 equiv) and n-butyl lithium (1.0 equiv) in THF to provide product 13 in 43% yield.66  
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Table 4 Conditions screened for direct Wittig rearrangement 
N
O
CF3
CF3
N
N
CF3
CF3
N
HO
conditions
-78 °C to rt
entry base (equiv) solvent results
1
2
3
4
5
Et2O 11a
n-BuLi (2.0) Et2O 13 (30%)b
THF dec.
n-BuLi (2.0) THF dec.
LiTMP/n-BuLi (1.0) THF
dec.
n-BuLi (1.2)
additive
TMEDA
TMEDA
DMPU
DMPU
none
6 LiTMP/n-BuLi (2.0) THF
13 (43%)b
none
11 13
n-BuLi (1.2)
 
a TLC showed starting material 11 as the main spot. 
b These are isolated yields. 
The Wittig-[1,2]-rearrangement step was not scalable (only up to a 60 mg reaction scale), 
and therefore limited the utility of this route. At this point, we decided to explore other routes for 
mefloquine synthesis.  
3.1.2 Oxidative decyanation route 
A few years after the Wittig rearrangement approach to mefloquine, a straightforward 
and high yielding synthesis based on the oxidative decyanation of a secondary aryl nitrile was 
reported.67 We selected this route to access the 6-SF5 analog 8a. To examine the feasibility of 
this chemistry, the sequence was followed to synthesize mefloquine, and most reactions afforded 
comparable results as reported in the literature (Scheme 5).67 After cyclization to form the 
hydroxyquinoline 9 under acidic conditions, the hydroxyl group was converted to the chloride 
using phosphorus oxychloride at 110 °C. Subsequent nucleophilic aromatic substitution by the 2-
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pyridylacetonitrile carbanion to the quinolyl chloride provided 19 in 91% yield. The desired aryl 
ketone 14 was obtained in 85% yield by oxidation with hydrogen peroxide under acidic 
conditions, and subsequent hydrogenation afforded mefloquine as a single anti-diastereomer.  
Scheme 5 A straightforward and high yielding synthesis of mefloquine. Literature yields are in the parentheses. 
N
N
CF3
CF3
NC
N
CF3
CF3
Cl
N
CN
NH2
EtO CF3
O O
CF3
2.  POCl3, 110 °C 
83% (85%)
NaH, PhMe, DMF
91% (91%)
N
N
CF3
CF3
O
PtO2, H2, HCl, EtOH, MeOH
29%
N
CF3
CF3
HO
N
HH2O2, AcOH, 75 °C
85% (95%)
1, single diastereomer
11 19
14
1.  PPA, 150 °C, 18%
18
  
Because the reactions in this route were reproducible and scalable using the CF3 
substrate, we decided to apply an analogous sequence for the SF5 building block to access the 6-
SF5 analog (Scheme 6). Condensation of the commercially available 2a and ethyl 4,4,4-
trifluoroacetoacetate in the presence of polyphosphoric acid led to 4-hydroxyquinoline 20a, 
which represents the first reported SF5-substituted quinoline compound. Chlorination with 
phosphorus oxychloride provided the corresponding 4-chloroquinoline 21a in good yields. 
Subsequent nucleophilic aromatic substitution by the 2-pyridylacetonitrile carbanion afforded the 
secondary nitrile 22a. Exposure to a mixture of hydrogen peroxide and acetic acid at 75 °C then 
provided the decyanated 4-quinolylketone 23a.   
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Scheme 6 Synthesis of 6-SF5 mefloquine analog 8a 
NH2
EtO CF3
O O
PPA, 150 °C
N
Cl
CF3
N CF3
NC
NN
CN
NaH, toluene, 
DMF, 85%
N CF3
O
NH2O2, AcOH
N
OH
CF3
POCl3, 110 °C
20a 21a
22a 23a
4-SF5-aniline 2a
N CF3
HO
N
HF5S
PtO2, H2, 
HCl
8a (dr > 20:1)
65%
77%
75 °C
89%
EtOH, 42%
F5S F5S F5S
F5S F5S
 
The concomitant reduction of the carbonyl and pyridyl groups in the presence of the 
quinoline ring was achieved using catalytic hydrogenation under acidic conditions (Table 5). 
This step of the synthesis proved to be problematic. The main side reaction is over-reduction of 
the quinoline moiety. In entry 1, the major compound isolated after the reaction showed M + 2 
ion peak in MS analysis. When the less active catalyst palladium on carbon was used, only the 
ketone was reduced and the alcohol 24 was isolated with 50% yield. This intermediate showed 
up on TLC immediately in the reaction catalyzed by platinum oxide and disappeared while the 
desired product 8a was formed. After screening different solvents, acids, and catalysts, optimal 
conditions for substrate 23a were found to be 0.4 equivalent of platinum oxide in ethanol 
containing hydrochloric acid, followed by recrystallization of crude 8a in MeOH (Table 5). After 
recystallization, 8a was obtained as one predominating diastereomer (dr > 20:1).  
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Table 5 Conditions screened for selective reduction of 23a 
N CF3
O
N
23a
N CF3
HO
N
HF5S
H2 (balloon)
conditions
8a
F5S
entry solvent results
1
3
time (h)
1.5
2.0
over-reduceda
8a (42%)b
catalyst (%) acid (equiv)
EtOH/MeOH (1:1)PtO2 (20)
PtO2 (40) HCl (5.0)
2
4
5.0 8a (25%)bPtO2 (40)
14 24 (50%)bPd/C (3) EtOH
EtOH
EtOH
HCl (1.2)
HCl (6.0)
AcOH (40)
N CF3
HO
N
F5S
24
rt
 
a The main compound after reaction was isolated and its MS was M(8a) + 2, detected by LC/MS . 
b These are isolated yields. 
 This diastereomer was assigned to be anti according to the analysis of coupling constants 
in the 1H NMR spectra. The J value of the 9-proton and 10-proton in mefloquine 1 is 6.0 Hz 
while it is 3.0 Hz in the syn-diastereomer 1a.68 For compound 8a, the coupling constant is 4.8 
Hz, which is closer to mefloquine than 1a. Thus, compound 8a was assigned as anti structure. 
Later X-ray crystallography study of 7-SF5 analog 8b (J = 4.8 Hz for 9-proton and 10-proton) 
confirmed the anti relative stereochemistry of these two chiral centers. 
N
CF3
CF3
HO
N
H
1
N
CF3
CF3
HO
N
H
1a
N CF3
HO
N
H
8a
N CF3
HO
N
H
8b
F5S
F5S
9 10 10 10 109 9 9
1
2
3
45
6
7
8
11 12
13
14
15
 
Figure 9 Diastereomer of mefloquine and relative stereochemistry of 8a and 8b 
The diastereoselectivity of this reduction reaction was thought to be caused by steric 
hindrance of the quinolyl group. Because alcohol 24 was observed on TLC as the intermediate 
between the ketone starting material 23a and product 8a, we assumed that in acidic conditions 
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the oxygen atom in 24 formed an hydrogen bond with the proton on the pyridinium nitrogen, and 
this locked conformation has the rear of the pyridine much more accessible than the front (Figure 
10). Thus, the hydrogen absorbed on platinum catalyst approached the pyridine from the less 
hindered rear face to form the desired diastereomer. 
N CF3
HO
N
F5S
24
H
H H Pt catalyst
from the rear
 
Figure 10 Possible mechanism of the diatereoselectivity of the reduction reaction 
3.2 SYNTHESIS OF THE 7-SF5 MEFLOQUINE ANALOG 
Because the route for preparation of the 6-SF5 analog was successful, we decided to 
follow the same synthetic sequence to prepare the 7-SF5 analog 8b from commercially available 
3-SF5-aniline (2b) (Figure 11).  
N
N
H
HO
CF3
NH2
8
7
6
3-SF5-aniline (2b)7-SF5-quinolyl analog (8b)
F5S
F5S
 
Figure 11 The starting material chosen for the synthesis of the 7-SF5 analog  
The Conrad-Limpach reaction of 2b and ethyl 4,4,4-trifluoroacetoacetate provided 
exclusively the desired 4-hydroxy-7-SF5-quinoline 20b in 75% yield. The absence of the 5-SF5-
quinoline isomer is probably due to the large steric demand of the SF5 group and/or electrostatic 
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repulsion of the 4-hydroxy substituent. Subsequent chlorination, substitution and oxidation went 
smoothly, affording the desired products in good yields.  
Scheme 7 Synthesis of the 7-SF5 mefloquine analog 8b 
NH2
EtO CF3
O O
PPA, 150 °C
N
Cl
CF3
N CF3
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NN
CN
NaH, toluene, 
DMF, 92%
N CF3
O
NH2O2, AcOH
N
OH
CF3
POCl3, 110 °C
20b 21b
22b 23b
3-SF5-aniline 2b
N CF3
HO
N
H
PtO2, H2, 
AcOH, EtOH
8b ( dr >20:1)
75%
78%
75 °C
92%
46%
F5S F5S F5S
F5S F5S F5S
5
 
The selective reduction of 23b demanded different conditions than its 6-SF5 congener 
23a. 7-SF5 analog 8b was best obtained in the presence of milder acid (AcOH) as opposed to the 
use of hydrochloric acid (Table 6). The low yield in HCl conditions may be due to the over-
reduction of the quinoline ring because HCl is strong enough to form the quinolinium ion and 
accelerate the reduction of the quinoline. 
Table 6 Conditions screened for the selective reduction of 23b 
N CF3
O
N
23b
N CF3
HO
N
H
H2 (balloon), PtO2
conditions
8b
entry yield
1a
time (h)
0.5
PtO2 (equiv) acid (equiv)
0.2
2 3.0 46%0.4
HCl (2.5)
AcOH (60)
F5S F5S
22%
EtOH
9 10
 
a The starting material was subjected to PtO2 (0.1 equiv), HCl (1.2 equiv) and EtOH/MeOH (1:1) conditions first. 
There was no desired product after 2 h and the reaction mixture was filtered and concentrated. The residue was then 
subjected to the conditions in the table. 
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Gratifyingly, the reduction was highly selective and afforded the desired anti-
diastereomer. Furthermore, slow evaporation of a methanolic solution of 8b provided needle-like 
crystals suitable for X-ray diffraction analysis (Figure 12). The sulfur atom of the SF5 group is 
situated in an octahedral environment, and the disposition of the two stereocenters is anti as in 
mefloquine. The dihedral angle of H-C(9)-C(10)-H is 72°, which matches its J value (4.8 Hz) in 
the Karplus equation. Since the 6-SF5 analog 8a has the same coupling constant of these two 
protons, it is also assigned as the anti-diastereomer. The crystal system is monoclinic and its unit 
cell contains both enantiomers and two MeOH molecules.   
 
Figure 12 The unit cell of X-ray structure of 8b 
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3.3 BIOLOGICAL EVALUATION OF ANALOGS 8a AND 8b 
Biological data were collected by the Division of Experimental Therapeutics, Walter 
Reed Army Institute of Research. The antimalarial activities and selectivities of 8a and 8b were 
compared to those of mefloquine and mefloquine analogs in which the quinoline ring was 
substituted at the 6- and 7-positions with a trifluoromethyl group (25 and 26, Figure 13).  
N CF3
HO
N
H
25
N CF3
HO
N
H
26
F3C
F3C 6
7
N CF3
HO
N
H
8b
F5SN CF3
HO
N
HF5S
8a
N CF3
HO
N
H
1, mefloquine
CF3
6
7
 
Figure 13 Structures of mefloquine and its analogs 
The 50% and 90% inhibitory concentrations (IC50s and IC90s) against the chloroquine-
resistant P. falciparum strain PfW2 and three mefloquine-resistant strains, PfD6, PfC235 and 
PfC2A, and the lethal concentration (LC50s) against a mammalian cell line were determined as 
previously described (Table 7).69  
Table 7 Antimalarial activity and toxicity of selected quinoline methanols. The units are ng/mL for IC50, IC90 and 
LC50 data. The selectivity index (SI) is the ratio of the LC50 against RAW macrophages relative to the PfW2 IC50. 
Pf W2 Pf D6 Pf C235 Pf C2A
1
8a
8b
25
26
2.5  9.8 8.0  20 18  63 22  87
3.3  11 9.2  33 9.8  39 14  52
3.3  13 12  45 12  47 16  80
21  130
13  60
5.0  16
3.0  17
17  67
12  37
53  140
30  86
analogs
IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
RAW
LC50
SI
5064
13740
ND
ND
ND
2026
4164
ND
ND
ND
 
The 6-SF5 analog 8a exhibited generally equivalent or lower IC50 and IC90 values, with 
greater selectivities than its CF3-congener 25 and mefloquine. The IC50 and IC90 values of the 7-
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SF5 analog 8b were generally equivalent to those of the CF3-congener 26 and mefloquine. These 
data demonstrate the effective biological mimicry as well as the considerable pharmaceutical 
potential of substituting the CF3 group with the SF5 group in quinoline containing antimalarials. 
3.4 SYNTHESIS OF THE 8-SF5 MEFLOQUINE ANALOG 
In the previous biological evaluation of mefloquine analogs, both 6- and 7-SF5 analogs 
(8a and 8b) exhibited better activity than their 6- and 7-CF3-congeners (25 and 26). This 
encouraging finding demonstrated the effective biological mimicry of the CF3-SF5 switch in 
quinoline containing antimalarial drugs and prompted us to prepare the synthetically 
considerably more challenging 8-SF5-congener 27 of mefloquine. According to the previous 
synthetic route, the target can be accessed from ortho-SF5-aniline 28 (Figure 14). 
N
N
H
HO
CF3
NH2
8
7
6
2-SF5-aniline (28)8-SF5-quinolyl analog (27)
SF5
SF5
 
Figure 14 The starting material chosen for the synthesis of the 8-SF5 analog 
Given the absence of a practical, high-yielding method for installing the SF5 group, there 
are still only a very limited number of SF5-containing building blocks accessible. In the case of 
SF5-arenes, oxidative fluorination of bis-nitrophenyl disulfide is still the generally preferred 
procedure. All improved routes involved expensive silver difluoride or highly dangerous fluorine 
gas, and the yields are generally low (<40%). Furthermore, the disulfide method is only 
applicable to a few substituted benzenes. In contrast to meta/para-nitro-SF5-benzene, the 
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corresponding ortho-nitro product is not formed. To date, the only substrate containing an ortho-
substituent suitable for direct fluorination is the bis-ortho-fluorodiphenyl disulfide. The desired 
starting material ortho-SF5-aniline 28 has not been made before.  
Because the disulfide fluorination conditions are dangerous, harsh, and low yielding, as 
well as unsuccessful for the preparation of the ortho-substituted SF5 arene, we envisioned 
installing the ortho-amino group by regioselective nitration of a suitable pentafluorosulfanyl 
arene, followed by reduction.70 Accordingly, we chose the commercially available 3-SF5-phenol 
29 as the nitration substrate because the strong electron-donating effect of the hydroxyl group 
should direct the nitro group to the ortho-position of the SF5 moiety. However, the 
regioselectivity of the nitration of the phenol was poor, presumably because the hydroxyl group 
activates the benzene ring, resulting in the formation of all possible ortho/para-nitrated products 
(eq 12).   
SF5 SF5
HO HO
NO2
SF5SF5
HO
HO
O2N
NO2
70% HNO3
30%
+ +
9%13%
r.t., 2 h
3-SF5-phenol 29
(12)
 
To diminish the strong ortho-directing effect, phenol 29 was converted to the less 
electron-donating trifluoromethane sulfonate 30 in 90% yield, and nitration now proceeded in 
75% yield to give exclusively the desired para-nitrated product 31, where the nitro group is 
placed ortho to the SF5 group (Scheme 8).  
Scheme 8 Successful regioselective nitration to generate the ortho-nitro SF5 benzene 
SF5
HO
SF5
TfO
Tf2O, Py, 90% fuming HNO3, H2SO4
40 °C, 75%
SF5
TfO
NO2
29 30 31  
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We envisioned that the removal of the triflate group and the reduction of the nitro group 
could be achieved via a single step of hydrogenation catalyzed by palladium on carbon under 
basic conditions.71 However, these hydrogenation conditions provided only mixtures with no 
desired product (eq 13). The only useful isolated compound was the 2-SF5-(4-triflate)aniline 32, 
which was obtained in 5% yield, but it decomposed soon after recovery from flash column 
chromatography.  
SF5
TfO
NHOH
SF5
HO
SF5
TfO
TfO
NO2 NH2
+ +
NO2SF5
TfO
NO2
H2, Pd/C, Et3N
33% 26% 5% 32 5%
+
MeOH, 3 h
31
(12)
 
We changed the strategy to a stepwise conversion of triflate and nitro groups to produce 
the important intermediate 28. Reduction of the nitro group seemed feasible by hydrogenation 
(eq 12). This transformation was conducted by applying the harsher conditions based on our 
previous results and provided aniline 32 in 80% yield (eq 13).72 This intermediate turned from 
colorless to black directly after concentration of the chromatography fractions. 1H NMR analysis 
of the black sample indicated partial decomposition. 
SF5
TfO
NO2
SF5
TfO
NH2
H2 (6 bar), Pd/C
AcOH, MeOH
4 h, 80%
31 32
(13)
 
With this aniline in hand, we examined reduction and hydrogen transfer conditions to 
remove the triflate group. The first reaction we tried was a newly reported reduction method 
using magnesium and palladium on carbon and it gave no conversion.73 Traditional 
hydrogenations conducted with palladium on carbon and a Raney-Ni reduction also failed. 
Starting material 32 was recovered in all these conditions. Standard hydrogen transfer with a 
palladium(II) catalyst also gave no reaction, even after heating at 80 °C in DMF for 4 days.74 
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Due to the difficulty of removing the triflate after reduction of the nitro group, we 
thought it might be feasible to remove it prior to nitro group reduction, because the electron-
withdrawing nature of the nitro group might facilitate the oxidative addition of the palladium 
catalyst. Two conditions with different hydrogen sources were examined in DMF. The first 
condition using triethylsilane gave the product with the SF5 group cleaved (eq 14), and the 
second, formic acid condition, gave only decomposition (eq 15).  
SF5
TfO
NO2 NO2
Pd(OAc)2, dppf
TfO
Et3SiH, DMF, 80 °C, 2 d
31
SF5
TfO
NO2
Pd(dppf)Cl2, Et3N
HCOOH, DMF, 80 °C, 4 h
31
decomposition
(14)
(15)
 
We assumed that the desired intermediate 28 was unstable and the removal of the triflate 
after the Conrad-Limpach reaction might be more feasible. Typical cyclization conditions using 
polyphosphoric acid at 150 °C with ethyl 4,4,4-trifluoroacetoacetate and 32 led to 
decomposition. Once the temperature was reduced to 130 °C, most of starting material was 
recovered (Scheme 9). 
Scheme 9 Attempted Conrad-Limpach cyclization of aniline 32 
SF5
TfO
NH2 N CF3
SF5
TfO
OH
EtO CF3
O O
PPA, 2 h
150 °C                       decomposition
130 °C                       mainly s.m.
32 33
  
Since all of these attempts failed, we revisited the triflate removal of the aniline 32. The 
failure of the hydrogen transfer process might be due to an unsuccessful oxidative addition of the 
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palladium catalyst to the oxygen-carbon bond; therefore, the more reactive 
tetrakis(triphenylphosphine) palladium(0) was employed instead of the palladium(II) precatalyst. 
In the presence of palladium(0), formic acid and triethylamine in dry dioxane, compound 32 was 
converted to the expected ortho-SF5-aniline 28 in 80% yield (crude) (eq 16). This novel 
compound is a colorless liquid at room temperature and solidifies upon cooling. 
SF5
TfO
NH2
32
Pd(PPh3)4, Et3N, HCOOH
dioxane, 105 °C, 1 h
SF5
NH2
28
80% (crude)
(16)
 
With this key intermediate in hand, we next focused our attention on the synthesis of the 
8-SF5 mefloquine analog according to the previous route (Scheme 10). The Conrad-Limpach 
reaction of 28 with ethyl 4,4,4-trifluoroacetoacetate in polyphosphoric acid led to the 8-SF5 
quinolyl intermediate 34 in 88% yield. The previously used chlorination conditions with 
phosphorous oxychloride at 110 °C proved to be too harsh for quinoline 34 and gave the product 
in low yield (18%). Milder conditions (thionyl chloride in DMF at 85 °C) afforded quinolyl 
chloride 35 in good yields. After nucleophilic aromatic substitution with 2-pyridyl-acetonitrile, 
oxidation of the carbon-nitrile bond, and Pt-catalyzed reduction of the ketone and pyridine 
moieties in 37, the target molecule 27 was obtained in moderate yields. This synthesis was used 
to prepare 27 on 100 mg scale.  
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Scheme 10 Synthesis of 8-SF5 analog 27 
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The J value of the 9- and 10-position protons is 3.6 Hz and the major diastereomer is 
assigned to be anti. This assignment was confirmed by X-ray crystallography of 27 (Figure 15). 
The dihedral angle of H-C(9)-C(10)-H is 64°, which matches its J value.  
 
Figure 15 X-ray structure of 27 
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3.5 BIOLOGICAL EVALUATION OF 27 
The in vitro antimalarial activity,69 cytotoxicity,69 permeability,75 plasma protein,76 and 
brain tissue binding properties76 of 8-SF5 mefloquine analog 27 were compared to those of 
mefloquine (1) and the 6- and 7-SF5 analogs 8a and 8b, respectively (Table 8). These biological 
data were collected by the Division of Experimental Therapeutics, Walter Reed Army Institute of 
Research and Biological Chemistry and the College of Life Sciences, University of Dundee. 
Table 8 Antimalarial activity, toxicity, permeability, plasma protein and brain tissue binding of mefloquine and its 
SF5 analogs 
analog
Pappc
A-B
MDCK
Fud
mouse
brain
Fud
mouse
plasma
Fud
human
plasma
1
27
16 92 182 183 9.4 0.002 0.0163 0.0305
9.6 74 91 165 5.0 0.0008 0.004 0.0072
Pf
W2
Pf
D6
Pf
C235
Pf
C2A RAW
LC90aIC90a
8a 19 55 91 110 13.8
8b 27 92 146 165 9.7
8934
8934
53604
6254
SIb
559
2795
230
932
NT
NT
NT
NT
NT
NT
 
aThe units are nM of IC90 and LC90 data. bThe selectivity index (SI) is the ratio of the LC90 against RAW 
macrophages relative to the Pf W2 IC90. cThe MDCK permeability is the apparent permeability in the A-B direction 
in MDR1-transfected MDCK cells in the presence of a PgP inhibitor (10 µM cyclosporine A). The units for apparent 
permeability are 10-6 cm/s. dFu in brain tissue and plasma protein binding studies represents the fraction of unbound 
drug. 
 
Analogs 27 and 8a were generally more potent than mefloquine against all the tested 
parasite strains and they were up to two-fold more potent and exhibited greater selectivity than 
analog 8b. Analog 27 has lower MDCK permeability than analog 8a and mefloquine, which 
indicates lower blood-brain barrier permeability. Accordingly, agent 27 outperformed other SF5-
analogs and would be predicted to be more efficacious in vivo than mefloquine. Furthermore, 27 
has moderately better selectivity than mefloquine. In the study of the unbound drugs in mouse 
brain, mouse plasma and human plasma, analog 27 has significantly fewer unbound fractions 
than mefloquine. This may also be advantageous if the affinity for the hERG receptor is similar, 
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and in vivo efficacy is not driven by the free plasma concentration. Overall, we anticipate that 
analog 27 will exhibit a superior safety profile at its minimum efficacious dose than mefloquine 
in vivo. 
3.6 SYNTHESIS OF SF5-DIAMINE ANALOGS 
In the early lead evaluation of the mefloquine analogs in the Division of Experimental 
Therapeutics, Walter Reed Army Institute of Research, it was found that the diamine analogs of 
mefloquine 38 and 39 (Figure 16) have high efficacy in curing mice with malaria.  
N
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N
CF3
CF3
HN
HO NH
N
SF5
CF3
HN
HO NH
N
SF5
CF3
HN
HO
H
N
38 39 40 41  
Figure 16 Diamine mefloquine analogs and their SF5-congeners 
Based on the biological data of the 8-SF5-mefloquine analogs, the 8-SF5-congeners of 38 
and 39 should be more efficacious. Compound 40 and 41 were designed for lead synthesis. Both 
of them could be obtained from epoxide opening of 42 by the corresponding amine. The epoxide 
could be synthesized through a Corey-Chaykovsky reaction of the aldehyde 43, which originates 
from the previously synthesized alcohol 34 (Fig. 17).  
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N
SF5
CF3
NHR
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N
SF5
CF3
O
N
SF5
CF3
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42 4340 and 41
N
SF5
CF3
OH
34  
Figure 17 Retrosynthetic plan for compounds 40 and 41 
Bromination of the quinolyl hydroxy 34 with phosphorous oxybromide gave the quinolyl 
bromide 44 in 85% yield. Treatment of 44 with Grignard reagent at 0 °C formed the quinolyl 
anion, which was trapped with dry DMF to provide the aldehyde 43 after work-up (Scheme 11).   
Scheme 11 Synthesis of the Corey-Chaykovsky precursor 43 
N CF3
CHO
N
SF5
CF3
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SF5
POBr3, 150 °C
85% N
SF5
CF3
Br
i-PrMgCl, THF, 0 °C;
DMF, 65%
34 44 43  
The traditional and the modified Corey-Chaykovsky conditions using trimethylsulfonium 
iodide, trimethyloxosulfonium iodide and dimethylsulfide, only gave complex mixtures after 
work-up, and no desired product was detected.  
We changed to an epoxidation strategy of the carbon-carbon double bond to prepare 42. 
To our delight, Stille coupling between quinolyl bromide 44 and tributylvinyltin catalyzed by 
tetrakis(triphenylphosphine)palladium(0) in dioxane afforded product 45 in 80% yield. We next 
examined the feasibility of the expoxidation. After several trials of standard conditions of 
epoxidation of the electrophilic double bond using mCPBA and UHP, this reaction proved to be 
problematic, and no product was detected (Scheme 12). 
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Scheme 12 Successful Stille coupling of substrate 43 and failed epoxidation of 45 
N CF3
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SF5
Pd(PPh3)4, tributylvinyltin
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SF5
N CF3
SF5
O
43 45 42
conditions
 
With 45 in hand, we tried a two-step protocol to obtain the epoxide. Sharpless 
asymmetric dihydroxylation of the exocyclic double bond with AD-mix-α and AD-mix-β 
provided two batches of enantiomerically enriched diols 46 in 76% and 82% yields, respectively. 
Subsequent tosylation of the primary alcohol followed by substitution afforded quinolyl epoxides 
42 in 80% and 69% yields. The enantiomeric excess of 42 from the synthesis using AD-mix-α 
was 41%, and another batch formed with AD-mix-β had an ee of 46% (Scheme 13, based on 
chiral SFC analysis). These two enantiomers can be separated by preparative SFC.      
Scheme 13 Asymmetric synthesis of quinolyl epoxide 42 
N CF3
SF5
N CF3
SF5
AD-mix-α
methanesulfonamide
water, t-BuOH, rt
76%
HO
OH
N CF3
SF5
O
NaH, THF
80%
45
(S)-42, 46% ee
[α]D21 = +24.5 (c, 0.70, CHCl3)
N CF3
SF5
N CF3
SF5
AD-mix-β
methanesulfonamide
water, t-BuOH, rt
82%
HO
OH
N CF3
SF5
O
45 (S)-46
(R)-42, 41% ee
[α]D21 = -20.9 (c, 0.76, CHCl3)
TsN
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The absolute stereochemistry was determined by X-ray crystallography of the pure 
enantiomer obtained from an SFC separation (Figure 18). This enantiomer was the main 
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component synthesized from the AD-mix-β and the stereocenter was assigned as (S) according to 
the X-ray. 
 
Figure 18 X-ray structure of the (S)-42 obtained from AD-mix-β  
The SFC separation of 40 mg 42 (20 mg synthesized from AD-mix-α and 20 mg from 
AD-mix-β) provided (R)-42 15 mg (89% ee) and (S)-42 in 12 mg (95% ee) quantity. With these 
enantiomers in hand, the epoxides were opened by the diamine 47 in good yields (Scheme 14). 
The t-Boc protection of the secondary amine proved to be necessary for good regioselectivity. 
The final deprotection of the t-Boc group went well under the HCl conditions and provided the 
pure target molecules 49 in good yields.   
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Scheme 14 Synthesis of target molecules (R)-49 and (S)-49 
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The biological evaluation of both enantiomers of 49 is pursued under the aspiration of in 
the Division of Experimental Therapeutics, Walter Reed Army Institute of Research. 
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4.0  CONCLUSION 
We have synthesized the 6-SF5 and 7-SF5 mefoquine analogs in 5 steps and 10-23% 
overall yields. These analogs were found to have equivalent or improved activities and 
selectivities against P. falciparum parasites in in vitro studies as opposed to the parent drug and 
the corresponding C-6 and C-7 trifluoromethyl isomers. Inspired by this result, the 8-SF5-
substituted mefloquine analog was synthezised in 9 steps from commercial starting materials and 
in 5 steps from a novel ortho-SF5-substituted aniline intermediate. Preclinical assays determined 
that this compound has improved activity against P. falciparum parasites and exhibits lower 
membrane permeability in an MDCK cell line screen, thus potentially reducing the adverse CNS 
effects of the parent antimalarial agent. These biological data demonstrate not only the effective 
biological mimcry but also the added potential therapeutic value that may be feasible with the 
CF3-SF5 switch strategy. Further in vivo studies of this 8-SF5 analog are underway. Other novel 
SF5-analogs synthesis are also in progress. 
During this work, the first SF5-substituted quinolines were reported, and a novel 
preparation of the versatile ortho-SF5-aniline was achieved.   
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4.1 EXPERIMENTAL SECTION 
General Information. Reactions were monitored by TLC analysis (pre-coated silica gel 
60 F254 plates, 250 µm layer thickness) and visualization was accomplished with a 254 nm UV 
light and by staining with a PMA solution (5 g of phosphomolybdic acid in 100 mL of 95% 
EtOH), p-anisaldehyde solution (2.5 mL of p-anisaldehyde, 2 mL of AcOH, and 3.5 mL of conc. 
H2SO4 in 100 mL of 95% EtOH), Vaughn’s reagent (4.8 g of (NH4)6Mo7O24 4 H2O and 0.2 g of 
Ce(SO4)2 in 100 mL of a 3.5 N H2SO4 solution) or a KMnO4 solution (1.5 g of KMnO4 and 1.5 g 
of K2CO3 in 100 mL of a 0.1% NaOH solution).  Flash chromatography on SiO2 was used to 
purify the crude reaction mixtures. 1H spectra were obtained at 300 or 600 MHz in CDCl3 unless 
otherwise noted.  Chemical shifts were reported in parts per million with the residual solvent 
peak used as an internal standard.  1H NMR spectra were obtained and are tabulated as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, qu=quintet, m = 
multiplet, app = apparent), number of protons, and coupling constant(s).  13C NMR spectra were 
obtained at 75 or 150 MHz using a proton-decoupled pulse sequence and are tabulated by 
observed peak. 19F NMR spectra were obtained at 282 MHz using a proton-decoupled pulse 
sequence in the presence of fluorobenzene as an internal standard.  
 
N
OH
CF3
20a
F5S
 
4-Hydroxy-6-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (20a). A solution of 4-
aminophenylsulfur pentafluoride (110 mg, 0.502 mmol) in polyphosphoric acid (7.0 mL) at 110 
°C was treated with ethyl 4,4,4-trifluoroacetoacetate (1.5 mL, 10.0 mmol) and heated up to 
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reflux at 150 °C for 3 h.  The reaction mixture was quenched with 5% NaOH solution (30 mL), 
extracted with EtOAc (2x), washed with brine, dried (MgSO4) and concentrated. The brown 
residue was purified by chromatography on SiO2 (25% EtOAc/Hexanes) to yield 20a (76.4 mg, 
44%) as a beige solid: Mp 252.0 °C (dec.); IR (neat) 3200-3000 (br), 2337, 1580, 1208, 1142, 
822, 777 cm -1; 1H NMR (acetone-d6) δ 8.68 (d, 1 H, J = 2.4 Hz), 8.23 (dd, 1 H, J =2.7, 9.3 Hz), 
8.09 (d, 1 H, J = 9.3 Hz), 7.03 (s, 1 H); 13C NMR (acetone-d6) δ 170.7, 151.4 (qu, 2JC-SF4 = 18.0 
Hz), 146.7, 135.1, 129.5 (appt, 2JC-SF4 = 4.5 Hz), 127.0, 123.5 (appt, 2JC-SF4 = 5.3 Hz), 122.0 (q, 
1JC-F = 272.3 Hz), 117.3, 105.5; 19F NMR δ 85.2 (qu, J = 145.5 Hz), 64.6 (d, J = 145.5 Hz), -
67.0; HRMS (TOF-ESI) m/z calcd for C10H6F8NOS (M + 1) 340.0042, found 340.0032.  
 
N
Cl
CF3
21a
F5S
 
4-Chloro-6-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (21a). After addition of 
preheated (60 °C) phosphorus oxychloride (108 mg, 0.701 mmol) to 20a (23.8 mg, 0.0702 
mmol), the reaction mixture was warmed to 110 °C and stirred at this temperature for 1.5 h. The 
conversion was monitored by TLC (10% EtOAc/Hexanes) and the solution was cooled down to 
room temperature upon the disappearance of the starting material, quenched with ice water (3.0 
mL), extracted with Et2O, washed with sat. NaHCO3 solution and brine, dried (MgSO4) and 
concentrated. The yellow residue was purified by chromatography on SiO2 (5% EtOAc/Hexanes) 
to provide 21a (19.3 mg, 77%) as a beige solid: Mp 107.9-109.0 °C; IR (neat) 2922, 1343, 1202, 
1135, 1100, 833, 818, 768 cm-1; 1H NMR δ 8.75 (d, 1 H, J = 2.4 Hz), 8.37 (d, 1 H, J = 9.3 Hz), 
8.22 (dd, 1 H, J = 2.4, 9.3 Hz), 7.96 (s, 1 H); 13C NMR δ 154.1 (qu, 2JC-SF4 = 18.0 Hz), 150.6 (q, 
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2JC-CF3 = 36.0 Hz), 148.3, 146.5, 132.0, 128.5 (appt, 2JC-SF4 = 4.5 Hz), 126.5, 123.4 (qu, 2JC-SF4 = 
5.3 Hz), 120.8 (q, 1JC-F = 273.8 Hz), 118.9 (appd, 2JC-SF4 = 2.3 Hz); 19F NMR δ82 (qu, J = 149.3 
Hz), 63.3 (d, J = 149.7 Hz), -67.9; EI-MS m/z 357 (M+, 100), 249 (55), 180 (70), 84 (75); HRMS 
(EI) m/z calcd for C10H4NF8SCl  356.9625, found 356.9622. 
 
N CF3
NC
N
22a
F5S
 
α-(2-Pyridyl)-6-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolylacetonitrile (22a). 
A cooled (0 - 5 °C) suspension of sodium hydride (11.9 mg, 0.494 mmol) in toluene (1.2 mL) 
and DMF (0.60 mL) was treated under Ar with a solution of 2-pyridylacetonitrile (27 µL, 0.247 
mmol) in toluene (0.60 mL) and DMF (0.15 mL) over 5 min. The resulting yellow-brown 
colored suspension was stirred for 1 h at the same temperature. A solution of 8a (58.9 mg, 0.165 
mmol) in toluene (1.2 mL) and DMF (0.50 mL) was added drop by drop to the suspension over 5 
min.  After 0.5 h, the reaction mixture was quenched with ice water (10 mL), extracted with 
EtOAc, washed with water (3x) and brine, dried (MgSO4) and concentrated. The orange residue 
was purified by chromatography on SiO2 (25% EtOAc/Hexanes) to provide 22a (62.0 mg, 86%) 
as a light orange solid: Mp 113.5-115.5 °C; IR (neat) 2251, 1187, 1141, 1109, 820 cm-1; 1H 
NMR δ 8.87 (d, 1 H, J = 2.1 Hz), 8.60 (appd, 1 H, J = 4.8 Hz), 8.37 (d, 1 H, J = 9.3 Hz), 8.18 (s, 
1 H), 8.16 (dd, 1 H, J = 2.1, 9.3 Hz), 7.78 (ddd, 1 H, J = 1.5, 7.5, 7.8 Hz), 7.53 (d, 1 H, J = 7.8 
Hz), 7.32 (appdd, 1 H, J = 4.8, 7.5 Hz), 6.09 (s, 1 H); 13C NMR δ 153.6 (qu, 2JC-SF4 = 18.8 Hz), 
152.8, 150.8 (q, 2JC-CF3 = 35.3 Hz), 150.5, 148.1, 144.6, 138.4, 132.3, 127.9 (appt, 2JC-SF4 = 3.8 
Hz), 125.4, 124.3, 123.4 (appt, 2JC-SF4 = 5.3 Hz), 122.6, 121.0 (q, 1JC-F = 273.8 Hz), 117.7 (d, 2JC-
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SF4 = 2.3 Hz), 117.2, 43.3; 19F NMR δ822 (qu, J = 149.2 Hz), 63.2 (d, J = 148.3 Hz), -67.8; EI-
MS m/z 439 (M+, 100), 311 (40), 78 (22); HRMS (EI) m/z calcd for C17H9N3F8S 439.0389, found 
439.0385. 
 
N CF3
O
N
23a
F5S
 
2-Pyridyl-6-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolylketone (23a). A 
suspension of 22a (60.0 mg, 0.137 mmol) in acetic acid (0.24 mL) was treated dropwise with 
H2O2 (53 µL, 0.683 mmol) at room temperature. The reaction mixture was placed in a preheated 
(75 °C) oil bath until the color turned to light yellow. The mixture was quenched with ice water 
(3.0 mL), extracted with Et2O, washed with sat. NaHCO3 solution and brine, dried (MgSO4) and 
concentrated. The yellow residue was purified by chromatography on SiO2 (16% 
EtOAc/Hexanes) to provide 23a (49.6 mg, 85%) as a white solid: Mp 122.0-124.0 °C; IR (neat) 
1683, 1182, 1133, 1105, 835, 820, 768, 764 cm-1; 1H NMR δ 8.65 (ddd, 1 H, J = 0.9, 1.5, 4.8 
Hz), 8.46-8.41 (m, 2 H), 8.39 (s, 1 H), 8.18 (dd, 1 H, J = 2.4, 9.6 Hz), 8.06 (ddd, 1 H, J = 1.8, 
7.8, 7.8 Hz), 8.01 (s, 1 H), 7.62 (ddd, 1 H, J = 0.9, 4.5, 7.5 Hz); 13C NMR δ 193.5, 153.8 (qu, 2JC-
SF4 = 18.0 Hz), 152.8, 149.9 (q, 2JC-CF3 = 36.0 Hz), 149.7, 148.0, 147.1, 137.9, 131.7, 128.5, 
127.7 (appt, 2JC-SF4 = 4.5 Hz), 125.3, 124.8 (appt, 2JC-SF4 = 5.3 Hz), 124.7, 121.2 (q, 1JC-F = 273.8 
Hz), 118.9 (d, 2JC-SF4 = 1.5 Hz); 19F NMR δ82.4 (qu, J = 151.9 Hz), 62.6 (d, J = 151.1 Hz), -67.8; 
EI-MS m/z 428 (M+, 30), 399 (40), 273 (100), 78 (80); HRMS (EI) m/z calcd for C16H8N2OF8S 
428.0230, found 428.0210. 
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α-(2-Piperidyl)-6-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolinemethanol (8a). 
A solution of 23a (20.0 mg, 0.0467 mmol) in conc. hydrochloric acid (58.0 µL, 0.233 mmol) and 
abs EtOH (0.56 mL) was treated with platinum oxide (4.2 mg, 0.0187 mmol). The reaction 
mixture was purged with hydrogen twice and hydrogenated under balloon pressure. After 2 h, 
there was no alcohol intermediate left by TLC analysis (10% MeOH/DCM). The mixture was 
filtered through florisil, concentrated, and extracted with Et2O. The combined organic layers 
were washed with sat NaHCO3 solution and brine, dried (MgSO4) and concentrated. The black 
residue was purified by chromatography on SiO2 (5% NEt3 in EtOAc then 5% NEt3 and 5% 
MeOH in EtOAc). The crude product was recrystallized to get pure 8a (8.5 mg, 42%) as a white 
solid and a dr 20:1: Mp 198 °C (dec.); IR (neat) 3000-2900 (br), 1368, 1258, 1139, 1105, 835, 
822, 798 cm-1; 1H NMR (acetone-d6, 600 MHz) δ 9.01 (d, 1 H, J = 2.4 Hz), 8.38 (d, 1 H, J = 9.0 
Hz), 8.31 (dd, 1 H, J = 2.4, 9.0 Hz), 8.16 (s, 1 H), 5.54 (d, 1 H, J = 4.8 Hz), 3.04 (ddd, 1 H, J = 
2.4, 5.4, 7.8 Hz), 2.97 (bd, 1 H, J = 8.4 Hz), 2.54 (dt, 1 H, J = 2.4, 12.0 Hz), 1.76-1.71 (m, 1 H), 
1.58-1.53 (m, 1 H), 1.51-1.46 (m, 1 H), 1.35-1.20 (m, 4 H); 13C NMR (acetone-d6, 600 MHz) 
δ 155.5, 153.0 (qu, 2JC-SF4 = 18.0 Hz), 150.6 (q, 2JC-CF3 = 34.5 Hz), 148.7, 132.7, 127.6 (appt, 2JC-
SF4 = 4.5 Hz), 127.2, 124.9 (appt, 2JC-SF4 = 4.5 Hz), 122.6 (q, 1JC-F = 273.0 Hz), 117.5 (d, 2JC-SF4 = 
1.5 Hz), 74.2, 62.6, 47.7, 28.0, 27.0, 25.2; 19F NMR δ84.7 (qu, J = 152.2 Hz), 64.5 (d, J = 149.5 
Hz), -66.8; HRMS (ESI) m/z calcd for C16H17N2OF8S (M + 1) 437.0928, found 437.0893. 
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4-Hydroxy-7-pentafluorosulfanyl-2-(trifluromethyl)quinoline (20b). A solution of 3-
aminophenylsulfur pentafluoride (110 mg, 0.502 mmol) in polyphosphoric acid (2.0 mL) at 110 
°C was treated with ethyl 4,4,4-trifluoroacetoacetate (1.5 mL, 10.0 mmol) and the mixture was 
heated up to 150 °C to reflux for 4 h.  The reaction mixture was quenched with 5% NaOH 
solution (30 mL), extracted with EtOAc (2x), washed with brine, dried (MgSO4) and 
concentrated. The crude brown residue was purified by chromatography on SiO2 (25% 
EtOAc/Hexanes) to yield 20b (128 mg, 75%) as a beige solid: Mp 261.2-262.2 °C; IR (neat) 
3200-3000 (br), 1580, 1277, 1198, 1157, 839, 820 cm -1; 1H NMR (acetone-d6) δ 8.48 (d, 1 H, J 
= 2.4 Hz), 8.47 (d, 1 H, J = 9.0 Hz), 8.05 (dd, 1 H, J = 2.4, 9.0 Hz), 7.27 (s, 1 H); 13C NMR 
(acetone-d6) δ 165.8, 156.0 (qu, 2JC-SF4 = 18.0 Hz), 149.9 (q, 2JC-CF3 = 35.3 Hz), 147.5, 127.2, 
125.5, 124.6, 124.0 (appt, 2JC-SF4 = 4.5 Hz), 122.5 (q, 1JC-F = 272.3 Hz), 104.1; 19F NMR δ 84.3 
(qu, J = 151.4 Hz), 64.0 (d, J = 151.4 Hz), -67.0; EI-MS m/z 339 (M+, 40), 231 (15), 137 (30), 95 
(30), 81 (100); HRMS (EI) m/z calcd for C10H5NOF8S 338.9964, found 338.9953. 
 
N
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4-Chloro-7-pentafluorosulfanyl-2-(trifluromethyl)quinoline (21b). After addition of 
preheated (60 °C) phosphorus oxychloride (306 mg, 1.99 mmol) to 20b (135 mg, 0.399 mmol), 
the reaction mixture was warmed to 110 °C and stirred at this temperature for 0.5 h. The 
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conversion was monitored by TLC (10% EtOAc/Hexanes) and the solution was cooled down to 
room temperature after the disappearance of the starting material, quenched with ice water (3.0 
mL), and extracted with Et2O. The combined organic layers were washed with sat. NaHCO3 
solution and brine, dried (MgSO4) and concentrated. The yellow residue was purified by 
chromatography on SiO2 (5% EtOAc/Hexanes) to provide 21b (112 mg, 78%) as a beige solid: 
Mp 94.8-96.8 °C; IR (neat) 1558, 1433, 1336, 1206, 1150, 1105, 1079, 835, 816 cm-1; 1H NMR 
δ 8.74 (d, 1 H, J = 2.1 Hz), 8.42 (d, 1 H, J = 9.3 Hz), 8.12 (dd, 1 H, J = 2.1, 9.3 Hz), 7.97 (s, 1 
H); 13C NMR δ 155.7 (qu, 2JC-SF4 = 18.8 Hz), 149.9 (q, 2JC-CF3 = 36.0 Hz), 147.1, 145.1, 129.5 
(appt, 2JC-SF4 = 5.3 Hz), 128.4, 126.4 (qu, 2JC-SF4 = 4.5 Hz), 125.5, 120.8 (q, 1JC-F = 274.5 Hz), 
119.6 (appd, 2JC-SF4 = 2.3 Hz); 19F NMR δ81.8 (qu, J = 149.5 Hz), 63.1 (d, J = 149.5 Hz), -67.8; 
EI-MS m/z 357 (M+, 50), 249 (25), 180 (25), 117 (30), 84 (100); HRMS (EI) m/z calcd for 
C10H4NF8SCl  356.9625, found 356.9630. 
 
N CF3
NC
N
22b
F5S
 
α-(2-Pyridyl)-7-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolylacetonitrile (22b). 
A cooled (0 – 5 °C) suspension of sodium hydride (19.9 mg, 0.830 mmol) in toluene (2.0 mL) 
and DMF (1.0 mL) was treated under Ar with a solution of 2-pyridylacetonitrile (46 µL, 0.415 
mmol) in toluene (1.0 mL) and DMF (0.25 mL) over 5 min. The resulting yellow-brown colored 
suspension was stirred for 1 h at the same temperature. A solution of 21b (98.9 mg, 0.277 mmol) 
in toluene (2.0 mL) and DMF (1.0 mL) was added drop by drop to the suspension over 5 min.  
After 0.5 h, the reaction mixture was quenched with ice water (10 mL), extracted with EtOAc, 
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washed with water (3x) and brine, dried (MgSO4) and concentrated. The orange residue was 
purified by chromatography on SiO2 (25% EtOAc/Hexanes) to provide 22b (111 mg, 92%) as an 
orange foam: IR (neat) 2249, 1588, 1435, 1366, 1258, 1187, 1142, 1111, 1085, 839, 811 cm-1; 1H 
NMR δ 8.73 (d, 1 H, J = 2.1 Hz), 8.60 (ddd, 1 H, J = 0.9, 1.5, 4.8 Hz), 8.35 (d, 1 H, J = 9.3 Hz), 
8.14 (s, 1 H), 8.03 (dd, 1 H, J = 2.4, 9.6 Hz), 7.79 (ddd, 1 H, J = 1.8, 7.8, 7.8 Hz), 7.49 (d, 1 H, J 
= 7.8 Hz), 7.33 (ddd, 1 H, J = 0.9, 4.8, 7.8 Hz), 6.08 (s, 1 H); 13C NMR δ 155.0 (qu, 2JC-SF4 = 
18.8 Hz), 152.7, 150.6, 150.1 (q, 2JC-CF3 = 36.0 Hz), 147.0, 143.1, 138.4, 129.9 (appt, 2JC-SF4 = 4.5 
Hz), 127.5, 126.2 (appt, 2JC-SF4 = 4.5 Hz), 125.0, 124.3, 126.6, 121.0 (q, 1JC-F = 274.5 Hz), 118.9 
(d, 2JC-SF4 = 2.3 Hz), 117.3, 43.0; 19F NMR δ81.8 (qu, J = 152.3 Hz), 63.0 (d, J = 152.3 Hz), -
67.6; EI-MS m/z 439 (M+, 35), 412 (10), 119 (30), 91 (100), 84 (60); HRMS (EI) m/z calcd for 
C17H9N3F8S 439.0389, found 439.0380. 
 
N CF3
O
N
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2-Pyridyl-7-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolylketone (23b). To a 
suspension of 22b (109 mg, 0.248 mmol) in acetic acid (0.43 mL) was added H2O2 (98 µL, 1.24 
mmol) dropwise at room temperature. The reaction mixture was placed in a preheated (75 °C) oil 
bath until the color turned to light yellow. The mixture was quenched with ice water (10 ml), 
extracted with Et2O, washed with sat. NaHCO3 solution and brine, dried (MgSO4) and 
concentrated. The yellow residue was purified by chromatography on SiO2 (16% 
EtOAc/Hexanes) to provide 23b (98.0 mg, 92%) as a white solid: Mp 99.5-101.1 °C; IR (neat) 
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1687, 1437, 1189, 1135, 1105, 826, 813, 801 cm-1; 1H NMR δ 8.78 (d, 1 H, J = 2.1 Hz), 8.64 
(ddd, 1 H, J = 0.9, 1.5, 4.8 Hz), 8.38 (appd, 1 H, J = 7.2 Hz), 8.07 (d, 1 H, J = 9.6 Hz), 8.01 (dd, 
1 H, J = 1.8, 7.8 Hz), 8.00 (s, 1 H), 7.99 (ddd, 1 H, J = 2.4, 9.3, 9.3 Hz), 7.61 (ddd, 1 H, J = 1.2, 
4.8, 7.8 Hz); 13C NMR δ 193.8, 154.9 (qu, 2JC-SF4 = 18.8 Hz), 152.9, 149.8, 149.2 (q, 2JC-CF3 = 
36.0 Hz), 146.9, 146.2, 137.8, 129.4 (appt, 2JC-SF4 = 4.5 Hz), 128.5, 127.3, 126.7, 126.0 (appt, 
2JC-SF4 = 4.5 Hz), 124.5, 121.2 (q, 1JC-F = 273.4 Hz), 119.3 (d, 2JC-SF4 = 2.3 Hz); 19F NMR δ82.2 
(qu, J = 152.3 Hz), 63.1 (d, J = 152.3 Hz), -67.6; EI-MS m/z 428 (M+, 100), 399 (95), 331 (35), 
301 (40), 119 (50), 99 (50); HRMS (EI) m/z calcd for C16H8N2OF8S 428.0230, found 428.0231. 
 
N CF3
HO
N
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α-(2-Piperidyl)-7-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolinemethanol (8b) 
A solution of  23b (70.5 mg, 0.165 mmol) in acetic acid (0.57 mL, 9.88 mmol) and abs EtOH 
(1.1 mL) was treated with platinum oxide (15.0 mg, 0.0658 mmol). The reaction mixture was 
purged with hydrogen twice and hydrogenated under balloon pressure. After 4 h, there was no 
alcohol intermediate detected by TLC (10% MeOH/DCM). The solution was filtered through 
florisil, concentrated, and extracted with Et2O. The combined organic layers were washed with 
sat. NaHCO3 solution and brine, dried (MgSO4) and concentrated. The black residue was 
purified by chromatography on SiO2 (5% NEt3 in EtOAc then 5% NEt3 and 5% MeOH in 
EtOAc). The crude product was recrystallized from MeOH to get 33.1 mg (46%) of product as a 
white solid with a dr 20:1: Mp 179.2-180.2 °C; IR (neat) 3000-2900 (br), 1442, 1366, 1256, 
1182, 1139, 1109, 1083, 932, 848, 816 cm-1; 1H NMR (acetone-d6, 600MHz) δ 8.66 (d, 1 H, J = 
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2.4 Hz), 8.64 (d, 1 H, J = 9.6 Hz), 8.20 (s, 1 H), 8.17 (dd, 1 H, J = 2.4, 9.6 Hz), 5.54 (d, 1 H, J = 
4.8 Hz), 3.04 (ddd, 1 H, J = 3.0, 4.8, 10.8 Hz), 2.97 (dm, 1 H, J = 12.0 Hz), 2.55 (dt, 1 H, J = 2.4, 
12.0 Hz), 1.74-1.69 (m, 1 H), 1.50-1.42 (m, 2 H), 1.36-1.27 (m, 2 H), 1.22 (tq, 1 H, J = 3.6, 12.6 
Hz); 13C NMR (acetone-d6, 600 MHz) δ 154.9 (qu, 2JC-SF4 = 18.0 Hz), 154.2, 150.0 (q, 2JC-CF3 = 
34.5 Hz), 147.1, 129.7 (appt, 2JC-SF4 = 4.5 Hz), 129.3, 127.3, 125.3 (appt, 2JC-SF4 = 4.5 Hz), 122.6 
(q, 1JC-F = 273.0 Hz), 118.1 (d, 2JC-SF4 = 1.5 Hz), 73.4, 62.2, 47.6, 27.4, 27.0, 25.1; 19F NMR 
δ84.2 (qu, J = 149.5 Hz), 64.1 (d, J = 149.5 Hz), -66.7; HRMS (ESI) m/z calcd for 
C16H17N2OF8S (M + 1) 437.0928, found 437.0948. 
 
SF5
TfO
NO2
31  
4-Nitro-3-(pentafluorosulfanyl)phenyl trifluoromethanesulfonate (31). A solution of 
3-(pentafluorothio)phenol (0.998 g, 4.40 mmol) in distilled pyridine (5.0 mL) was treated with 
triflic anhydride (0.91 mL, 5.28 mmol) dropwise at 0 oC and stirred for 10 min at this 
temperature.  The reaction mixture was then allowed to stir at room temperature for 1.5 h, diluted 
with diethyl ether (40 mL), and extracted with a 1 M solution of copper sulfate (3x). The organic 
layer was washed with water and brine, dried (MgSO4) and concentrated. The residue was 
purified by chromatography on SiO2 (10% diethyl ether/pentane) to yield 3-
(pentafluorosulfanyl)phenyl trifluoromethanesulfonate (30) (1.40 g, 91%) as a colorless oil that 
was used immediately for the next reaction. 
A solution of 3-(pentafluorosulfanyl)phenyl trifluoromethanesulfonate (30) (1.40 g, 4.00 
mmol) in conc. sulfuric acid (13 mL) was slowly treated with fuming nitric acid (11 mL) at 0 °C. 
 61 
The reaction mixture was stirred for 7.5 h at 40 °C, quenched with ice (40 g), extracted with 
diethyl ether (40 mL), washed with sat. NaHCO3 (2x 30 mL) and brine, dried (MaSO4) and 
concentrated. The yellow residue was purified by chromatography on SiO2 (10 
%AcOEt/Hexanes) to provide compound 31 (1.25 g, 79%) as a white solid: Mp 70.2~71.8 °C; IR 
(neat) 3105, 1549, 1431, 1366, 1250, 1211, 1131, 822, 781, 749 cm-1; 1H NMR (acetone-d6) 
δ 8.48 (d, 1 H, J = 2.4 Hz), 8.26 (d, 1 H, J = 9.0 Hz), 8.20 (dd, 1 H, J = 2.1, 9.0 Hz); 13C NMR 
(acetone-d6) δ 150.5, 146.7, 144.8 (qu, 2JC-SF4 = 22.5 Hz), 129.3, 128.6, 124.4 (qu, 2JC-SF4 = 5.3 
Hz), 119.7 (q, 1JC-F = 318.0 Hz); 19F NMR (acetone-d6) δ 76.4 (qu, J = 155.1 Hz), 68.7 (d, J = 
152.3 Hz), -72.2; EIMS m/z 397 (M+, 4), 84 (75), 69 (99), 57 (100); HRMS (EI) m/z calcd for 
C7H3NO5F8S2 396.9325, found 396.9311. 
 
SF5
TfO
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32  
4-Amino-3-(pentafluorosulfanyl)phenyl trifluoromethanesulfonate (32). A solution of 
31 (126 mg, 0.317 mmol) in acetic acid (1.0 mL) and methanol (1.0 mL) was treated with Pd on 
carbon (10%) (33.8 mg, 0.0317 mmol). The reaction mixture was hydrogenated under 6 bar H2 
pressure in a Parr apparatus for 4 h and filtered through Celite. The filtrate was concentrated, 
extracted with diethyl ether, washed with sat. NaHCO3, water and brine, dried (MgSO4) and 
concentrated. The residue was purified by chromatography on SiO2 (10% diethyl ether/pentane) 
to provide 32 (96.7 mg, 83%) as a white solid: Mp 66.4~66.7 °C; IR (neat) 3547, 3431, 1634, 
1502, 1407, 1247, 1215, 1133, 850, 801 cm-1; 1H NMR (CDCl3) δ 7.51 (d, 1 H, J = 2.7 Hz), 7.20 
(dd, 1 H, J = 2.7, 9.0 Hz), 6.79 (d, 1 H, J = 9.0 Hz), 4.64 (bs, 2 H); 13C NMR (CDCl3) δ 141.9, 
138.9, 138.3 (qu, 2JC-SF4 = 17.2 Hz), 126.0, 122.0 (qu, 2JC-SF4 = 5.3 Hz), 120.2, 118.9 (q, 1JC-F = 
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318.8 Hz); 19F NMR (CDCl3) δ 85.6 (qu, J = 152.3 Hz), 64.4 (d, J = 149.5 Hz), -72.6; EIMS m/z 
367 (M+, 10), 234 (55), 106 (60), 84 (100), 69 (40); HRMS (EI) m/z calcd for C7H5NO3F8S2 
366.9583, found 366.9571. 
 
N
SF5
CF3
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34  
4-Hydroxy-8-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (34). To a solution of 
32 (1.46 g, 3.98 mmol) in anhydrous degassed dioxane (65 mL) at room temperature was added 
tetrakis(triphenylphosphine) palladium(0) (0.209 g, 0.199 mmol),  triethylamine (2.0 mL, 14.3 
mmol) and formic acid (0.54 mL, 14.3 mmol). The mixture was heated at reflux for 1 h under a 
nitrogen atmosphere, cooled to room temperature, and filtered through Celite.  The filtrate was 
concentrated and extracted with DCM, washed with water (3x) and brine, dried (MgSO4), and 
concentrated. The brown residue was purified by chromatography on SiO2 (1% triethylamine and 
10% diethyl ether in pentane) to provide crude 2-aminophenylsulfur pentafluoride (28) (0.700 g, 
3.19 mmol) as a colorless liquid.  
A solution of crude 2-aminophenylsulfur pentafluoride (28) (0.700 g, 3.19 mmol) in 
polyphosporic acid (10 mL) at 110 °C was treated with ethyl 4,4,4-trifluoroacetoacetate (4.3 mL, 
29.4 mmol) and heated at reflux at 150 °C for 1 h.  The reaction mixture was cooled to room 
temperature, quenched by addition of 40 g ice, neutralized to pH=5 by adding 5% NaOH 
solution and NaOH pellets, extracted with EtOAc (2x), washed with brine, dried (MgSO4), 
filtered and concentrated. The crude brown residue was purified by chromatography on SiO2 
(25% EtOAc/Hexanes) to yield 34 (0.980 g, 90% purity, 70% over two steps) as a beige solid: 1H 
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NMR (CDCl3) δ 8.89 (bs, 1 Η), 8.65 (d, 1 H, J = 7.8 Hz), 8.21 (dd, 1 H, J = 1.5, 8.1 Hz), 7.54 
(app t, 1 H, J = 8.1 Hz), 6.71 (d, 1 H, J = 1.5 Hz); 19F NMR (CDCl3) δ 84.9 (qu, J = 155.1 Hz), 
68.6 (d, J = 146.6 Hz), -68.7; EIMS m/z 339 (M+, 100), 211 (50), 183 (25); HRMS m/z calcd for 
C10H5F8NOS 338.9964, found 338.9954. 
 
N
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35  
4-Chloro-8-pentafluorosulfanyl-2-(trifluoromethyl)quinoline. A solution of 34 (0.373 
g, 0.990 mmol) in thionyl chloride (4.0 mL) was treated with a catalytic amount of DMF (6 
drops). The reaction mixture was heated to 80 °C and kept at reflux for 1 h. The mixture was 
cooled to 0 °C and quenched with 20 g of ice. The suspension was extracted with diethyl ether 
(20 mL). The organic layer was washed with sat. NaHCO3 (2x) and brine, dried (MgSO4) and 
concentrated. The yellow residue was purified by chromatography on SiO2 (15% 
EtOAc/Hexanes) to provide 4-chloro-8-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (35) 
(0.304 g, 86%) as a beige solid: Mp 108.7~109.6 °C; IR (neat) 1336, 1263, 1185, 1141, 1114, 
1021, 1075, 844, 818, 757, 721, 667 cm-1; 1H NMR (CDCl3) δ 8.59 (dd, 1 H, J = 1.2, 8.4 Hz), 
8.46 (dd, 1 H, J = 1.2, 7.8 Hz), 7.94 (s, 1 H), 7.87 (dd, 1 H, J = 8.1, 8.4 Hz); 13C NMR (CDCl3) δ 
151.8 (qu, 2JC-SF4 = 15.0 Hz), 148.4 (q, 2JC-CF3 = 36.0 Hz), 145.4, 142.0, 133.1 (app t, 2JC-SF4 = 4.5 
Hz), 129.4, 128.2, 128.2, 120.7 (q, 1JC-F = 274.5 Hz), 118.3 (app d, 2JC-SF4 = 1.5 Hz); 19F NMR 
(CDCl3) δ 83.6 (qu, J = 157.9 Hz), 71.7 (d, J = 177.7 Hz), -68.1; EIMS m/z 357 (M+, 100), 249 
(25), 149 (55), 180 (60), 89 (20); HRMS (EI) m/z calcd for C10H4NF8SCl  356.9625, found 
356.9633. 
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α-(2-Pyridyl)-8-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolylacetonitrile (36). 
A cooled (0 ~ 5°C) suspension of sodium hydride (38.8 mg, 1.54 mmol) in toluene (6.0 mL) and 
DMF (3.0 mL) was treated under argon gas with a solution of 2-pyridylacetonitrile (0.18 mL, 
1.66 mmol) in toluene (5.0 mL) and DMF (1.5 mL) for 10 min. The resulting yellow-brown 
colored suspension was stirred for 1 h at the same temperature. A solution of 4-chloro-8-
pentafluorosulfanyl-2-(trifluoromethyl)quinoline (0.458 g, 1.28 mmol) in toluene (8.0 mL) and 
DMF (3.0 mL) was added dropwise to the suspension over 5 min.  After 0.5 h, the reaction 
mixture was quenched with ice water (50 mL), extracted with EtOAc, washed with water (3x) 
and brine, dried (MgSO4) and concentrated. The orange residue was purified by chromatography 
on SiO2 (25% EtOAc/Hexanes) to provide 36 (0.450 g, 80%) as a light orange solid: Mp 146.2 
°C (dec.); IR (neat) 2876, 1368, 1275, 1179, 1144, 1122, 846, 833, 793, 654 cm-1; 1H NMR 
(CDCl3) δ 8.61 (ddd, 1 H, J = 0.9, 1.8, 5.1 Hz), 8.47 (d, 1 H, J = 8.7 Hz), 8.41 (dd, 1 H, J = 0.9, 
8.1 Hz), 8.10 (s, 1 H), 7.79 (dd, 1 H, J = 8.1, 8.4 Hz), 7.78 (ddd, 1 H, J = 2.1, 7.8, 7.8 Hz), 7.46 
(d, 1 H, J = 8.1 Hz), 7.33 (ddd, 1 H, J = 0.9, 5.1, 7.5 Hz), 6.07 (s, 1 H); 13C NMR (CDCl3) δ 
153.0, 152.4 (qu, 2JC-SF4 = 15.8 Hz), 150.6, 148.7 (q, 2JC-CF3 = 36.0 Hz), 143.2, 141.9, 138.4, 
132.6 (app t, 2JC-SF4 = 5.3 Hz), 128.6, 128.2, 127.3, 124.3, 122.6, 120.9 (q, 1JC-F = 273.8 Hz), 
117.5, 117.4, 43.4; 19F NMR (CDCl3) δ 83.7 (qu, J = 157.9 Hz), 71.6 (d, J = 169.2 Hz), -68.1; 
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EIMS m/z 439 (M+, 60), 428 (25), 273 (25), 89 (30), 78 (100); HRMS (EI) m/z calcd for 
C17H9N3F8S  439.0389, found 439.0388. 
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2-Pyridyl-8-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolylketone (37). A 
suspension of 36 (197 mg, 0.448 mmol) in acetic acid (2.6 mL) was treated with H2O2 (0.35 mL, 
4.48 mmol) dropwise at room temperature. The reaction mixture was placed in a preheated (75 
°C) oil bath until it turned to light yellow. The mixture was quenched with ice water (10 mL), 
extracted with diethyl ether (10 mL), washed with sat. NaHCO3 solution and brine, dried 
(MgSO4) and concentrated. The yellow residue was purified by chromatography on SiO2 (16% 
EtOAc/Hexanes) to provide 2-pyridyl-8-pentafluorosulfanyl-(2-trifluoromethyl)-4-
quinolylketone (37) (171 mg, 89%) as a white solid: Mp 98.9~99.7 °C; IR (neat)1687, 1271, 
1245, 1211, 1182, 1137, 1114, 844, 829, 759, 731 cm-1; 1H NMR (CDCl3) δ 8.62 (ddd, 1 H, J = 
0.9, 1.8, 4.5 Hz), 8.42 (dd, 1 H, J = 1.2, 7.8 Hz), 8.38 (ddd, 1 H, J = 0.9, 0.9, 8.1 Hz), 8.12 (dd, 1 
H, J = 1.2, 8.4 Hz), 8.04 (ddd, 1 H, J = 1.8, 7.8, 7.8 Hz), 7.90 (s, 1 H), 7.72 (app t, 1 H, J = 8.1 
Hz), 7.60 (ddd, 1 H, J = 1.2, 4.5, 7.5 Hz); 13C NMR (CDCl3) δ 194.4, 152.9, 151.8 (appt, 2JC-SF4 
= 15.0 Hz), 149.8, 147.8 (q, 2JC-CF3 = 35.3 Hz), 147.2, 141.6, 137.8, 132.4 (appt, 2JC-SF4 = 5.3 
Hz), 130.6, 128.5, 127.8, 127.1, 124.4, 121.1 (q, 1JC-F = 273.8 Hz), 117.2 (d, 2JC-SF4 = 2.3 Hz); 
19F NMR (CDCl3) δ 84.1 (qu, J = 157.9 Hz), 71.7 (d, J = 149.5 Hz), -68.0; EIMS m/z 428 (M+, 
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65), 399 (100), 273 (95), 272 (30); HRMS (EI) m/z calcd for C16H8N2OF8S  428.0230, found 
439.0215. 
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α-(2-Piperidyl)-8-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolinemethanol (27). 
A solution of 2-pyridyl-8-pentafluorosulfanyl-(2-trifluoromethyl)-4-quinolylketone (37) (83.2 
mg, 0.194 mmol) in conc. hydrochloric acid (79 µL, 0.971 mmol) and abs EtOH (2.0 mL) was 
treated with platinum oxide (4.4 mg, 0.0194 mmol). The flask was purged with hydrogen twice 
and hydrogenated under balloon pressure of H2. After 2 h, no alcohol intermediate appeared on 
TLC (50% EtOAc/Hexanes to check for the alcohol intermediate by UV, followed by 75% 
dichloromethane/EtOH to check for the final product by UV and ninhydrin staining) anymore. 
The mixture was filtered through florisil, concentrated, extracted with diethyl ether (20 mL), 
washed with sat. NaHCO3 and NaOH aqueous solution (pKa = 13) and brine, dried (MgSO4) and 
concentrated. The yellow residue was purified by chromatography on SiO2 (5% triethylamine in 
EtOAc then 5% triethylamine and 5% MeOH in EtOAc). The crude product (65.0 mg) was 
crystallized from MeOH to obtain 6 (40.0 mg, 47%) as a white solid in a dr: 20>1: Mp 182.0 °C 
(dec.); IR (neat) 3088, 2937, 2600 (br), 1422, 1366, 1267, 1224, 1183, 1113, 846, 826, 785, 721, 
652 cm-1; 1H NMR (acetone-d6, 600 MHz) δ 8.75 (d, 1 H, J = 8.4 Hz), 8.58 (d, 1 H, J = 7.8 Hz), 
8.19 (s, 1 H), 7.97 (dd, 1 H, J = 7.8, 8.4 Hz), 5.58 (d, 1 H, J = 3.6 Hz), 3.03 (ddd, 1 H, J = 3.0, 
4.8, 10.8 Hz), 2.98 (app d, 1 H, J = 12.0 Hz), 2.56 (dt, 1 H, J = 3.0, 12.0 Hz), 1.72 (app d, 1 H, J 
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= 12.6 Hz), 1.47 (app d, 1 H, J = 12.6 Hz), 1.42 (app d, 1 H, J = 12.6 Hz), 1.39-1.22 (m, 2 H), 
1.57 (tq, 1 H, J = 3.6, 13.2 Hz); 13C NMR (acetone-d6, 600 MHz) δ 154.5, 152.1 (qu, 2JC-SF4 = 
13.5 Hz), 148.4 (q, 2JC-CF3 = 34.5 Hz), 141.7, 133.1 (appt, 2JC-SF4 = 4.5 Hz), 131.0, 129.1, 127.9, 
122.5 (q, 1JC-F = 273.0 Hz), 116.5 (d, 2JC-SF4 = 1.5 Hz), 73.5, 62.3, 47.6, 27.3, 27.0, 25.1; 19F 
NMR (acetone-d6) δ 86.6 (qu, J = 150.2 Hz), 72.8 (d, J = 144.7 Hz), -67.1; HRMS (ESI) m/z 
calcd for C16H17N2OF8S (M+1) 437.0934, found 437.0923. 
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4-Bromo-8-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (43). After addition of 
phosphorus oxybromide (160 mg, 0.557 mmol) to 34 (19.0 mg, 0.0557 mmol), the reaction 
mixture was warmed to 110 °C and stirred at this temperature for 0.5 h. The mixture was cooled 
to 0 °C and quenched with 20 g of ice. The suspension was extracted with diethyl ether (20 mL). 
The organic layer was washed with sat. NaHCO3 (2x) and brine, dried (MgSO4) and 
concentrated. The yellow residue was purified by chromatography on SiO2 (5% EtOAc/Hexanes) 
to provide 4-bromo-8-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (43) (19.1 mg, 85%) as a 
beige solid: 1H NMR (CDCl3) δ 8.57 (dd, 1 H, J = 0.9, 8.4 Hz), 8.46 (dd, 1 H, J = 1.2, 7.8 Hz), 
8.14 (s, 1 H), 7.86 (dd, 1 H, J = 7.8, 8.1 Hz); 13C NMR (CDCl3) δ 151.7 (qu, 2JC-SF4 = 15.0 Hz), 
148.3 (q, 2JC-CF3 = 36.0 Hz), 141.8, 136.5, 133.1 (app t, 2JC-SF4 = 5.3 Hz), 132.1, 129.5, 128.3, 
122.1 (app d, 2JC-SF4 = 1.5 Hz), 120.5 (q, 1JC-F = 274.5 Hz); 19F NMR (CDCl3) δ 83.2 (qu, J = 
149.5 Hz), 71.7 (d, J = 152.3 Hz), -68.1. 
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4-ethenyl-8-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (45). A solution of 43 
(30.0 mg, 0.0747 mmol) in dry degassed dioxane (1.5 mL) was treated with 
tetrakis(triphenylphosphine)palladium(0) (15.7 mg, 0.0149 mmol) and tri-n-butyl(vinyl)tin (27 
µL, 0.0895 mmol). The reaction mixture was heated to 105 °C and kept at reflux for 1 h. The 
mixture was cooled to rt and quenched with KF (34.0 mg in 1.0 mL water). The suspension was 
extracted with diethyl ether (20 mL). The organic layer was washed with brine, dried (MgSO4) 
and concentrated. The yellow residue was purified by chromatography on SiO2 (15% 
EtOAc/Hexanes) to provide 45 (20.9 mg, 80%) as a white solid: Mp 108.7~109.6 °C; IR (neat) 
1193, 1139, 1120, 833, 824, 759, 732 cm-1; 1H NMR (CDCl3) δ 8.41 (s, 1H), 8.38 (d, 1 H, J = 
1.8 Hz), 7.87 (s, 1 H), 7.76 (dd, 1 H, J = 8.1, 8.1 Hz), 7.44 (dd, 1 H, J = 11.1, 17.1 Hz), 6.09 (d, 1 
H, J = 17.1 Hz), 5.85 (d, 1 H, J = 11.1 Hz); 13C NMR (CDCl3, 600 MHz) δ 152.0 (qu, 2JC-SF4 = 
13.5 Hz), 148.6 (q, 2JC-CF3 = 36.0 Hz), 146.9, 141.6, 132.1 (qu, 2JC-SF4 = 4.5 Hz), 131.5, 128.8, 
128.0, 126.9, 123.8, 121.3 (q, 1JC-F = 274.5 Hz), 114.4; 19F NMR (CDCl3) δ 84.5 (qu, J = 155.1 
Hz), 71.5 (d, J = 153.3 Hz), -68.2; EIMS m/z 349 (M+, 5), 222 (50), 202 (100), 152 (90), 127 
(70), 89 (90), 69 (85). 
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4-(1,2-dihydroxyethyl)-8-pentafluorosulfanyl-2-(trifluoromethyl)quinoline (46). A 
round-bottom flask was charged with a stir bar, AD-mix-α (0.401 g) and methanesulfonamide 
(0.0887 g, 0.904 mmol). Water (1.7 mL) and t-BuOH (1.7 mL) were added, and the mixture was 
cooled to 0 °C. Olefin 45 (0.0987 g, 0.283 mmol) in t-BuOH (1.0 mL) was added to the mixture 
and the reaction was sirred for 2 h at rt. Sodium sulfite (0.500 g) was added and the reaction was 
stirred for 1 h. The reaction was pored into water (40 mL), extracted with DCM (3x) and the 
organic layer was dried (Na2SO4) and concentrated. The residue was purified by chromatography 
on SiO2 (50% EtOAc/Hexanes) to provide 46 (0.107 g, 99%) as a white solid: Mp 176.9~178.2 
°C; IR (neat) 3258, 1137, 1182, 1120, 1087, 1029, 854, 833, 824 cm-1; 1H NMR (acetone-d6) δ 
8.73 (d, 1 H, J = 8.5 Hz), 8.58 (d, 1 H, J = 8.0 Hz), 8.25 (s, 1 H), 7.98 (dd, 1 H, J = 8.0, 8.5 Hz), 
5.77 (t, 1 H, J = 5.5), 5.23 (s, 1 H), 4.20 (s, 1 H), 3.97 (dd, 1 H, J = 4.5, 11.5), 3.85 (dd, 1 H, J = 
6.0, 11.0); 13C NMR (acetone-d6) δ 154.4, 152.1 (qu, 2JC-SF4 = 12.8 Hz), 148.6 (q, 2JC-CF3 = 34.5 
Hz), 141.6, 133.1 (qu, 2JC-SF4 = 5.3 Hz), 130.8, 129.1, 128.0, 122.5 (q, 1JC-F = 273.0 Hz), 116.2 
(app d, 2JC-SF4 = 2.3 Hz), 71.7, 68.0; 19F NMR (acetone-d6) δ 84.9 (qu, J = 146.6 Hz), 71.1 (d, J = 
146.6 Hz), -68.8; EIMS m/z 383 (M+, 90), 353 (100), 225 (30), 197 (25), 128 (25), 69 (25), 57 
(35). 
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4-[(2S)-oxiran-2-yl]-8-(pentafluorosulfanyl)-2-(trifluoromethyl)quinoline (42). A 
solution of 46 (0.0780 g, 0.204 mmol) in dry THF (1.5 mL) was treated with NaH (0.0103 g, 
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0.407 mmol) and N-(p-toluenesulfonyl)imidazole (0.114 g, 0.509 mmol). The reaction was 
stirred for 1 h and it was quenched with water, extracted with diethyl ether (3*) and the organic 
layer was dried (Na2SO4) and concentrated. The residue was purified by chromatography on 
SiO2 (20% EtOAc/Hexanes) to provide 42 (0.0596 g, 80%) as a white solid: Mp 106.9~108.1 °C; 
[α]D21 -20.9 (c 0.76, CHCl3); 41% ee; IR (neat) 1191, 1131, 1114, 841, 826, 807, 766, 732 cm-1; 
1H NMR (CDCl3) δ 8.42 (d, 2 H, J = 8.1 Hz), 7.82 (dd, 2 H, J = 7.5, 8.4 Hz), 4.54 (dd, 1 H, J = 
2.7, 3.6 Hz), 3.44 (dd, 1 H, J = 4.2, 5.4 Hz), 2.83 (dd, 1 H, J = 2.4, 5.4 Hz); 13C NMR (CDCl3) δ 
152.1 (qu, 2JC-SF4 = 14.3 Hz), 149.0 (q, 2JC-CF3 = 36.0 Hz), 147.1, 140.9, 132.2 (qu, 2JC-SF4 = 4.5 
Hz), 128.2, 127.9, 127.5, 121.1 (q, 1JC-F = 273.8 Hz), 113.4 (app d, 2JC-SF4 = 2.3 Hz), 51.0, 49.6; 
19F NMR (CDCl3) δ 84.1 (qu, J = 149.5 Hz), 71.5 (d, J = 152.3 Hz), -68.3; EIMS m/z 365 (M+, 
5), 238 (25), 210 (35), 127 (40), 89 (100), 69 (100). 
4-[(2S)-oxiran-2-yl]-8-(pentafluorosulfanyl)-2-(trifluoromethyl)quinoline(42). [α]D21 
+24.5 (c 0.70, CHCl3); 46% ee. 
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tert-butyl N-cyclopropyl-N-(2-{[(2s)-2-hydroxyl-2-[8-pentafluorosulfanyl)-2-(trifluo- 
romethyl)quinolin-4-yl]ethyl]amino}ethyl)carbamate (48). A solution of S-42 (0.0090 g, 
0.0246 mmol) in EtOH (0.8 mL) was treated with t-butyl N-(2-aminoethyl)-N-cyclopropyl 
carbamate (0.0054 g, 0.0296 mmol). The mixture was irradiated at 155 °C by microwave for 1 h 
and was concentrated to afford light yellow oil. The residue was purified by chromatography on 
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SiO2 (2% MeOH and 0.5% NH4OH in DCM) to provide 48 (0.0113 g, 81%) as a white solid: 1H 
NMR (CDCl3) δ 8.38 (dd, 1 H, J = 1.2, 8.1 Hz), 8.29 (d, 1 H, J = 8.1 Hz), 8.16 (s, 1 H), 7.75 (dd, 
1 H, J = 8.1, 8.1 Hz), 5.51 (dd, 1 H, J = 3.6, 8.7 Hz), 3.38 (m, 2 H), 3.25 (dd, 1 H, J = 3.6, 12.6 
Hz), 2.92 (m, 2 H), 2.78 (dd, 1 H, J = 8.4, 12.3 Hz), 2.52 (ddd, 1 H, J = 3.9, 7.2, 10.8 Hz), 1.47 
(s, 9 H), 0.77 (m, 2 H), 0.61 (m, 2 H). 
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(1S)-2-{[2-(cyclopropylamino)ethyl]amino}-1-[8-pentafluorosulfanyl)-2-(trifluoro- 
methyl)quinolin-4-yl]ethanol (48). A solution of S-48 (0.0110 g, 0.0200 mmol) in Et2O (0.1 
mL) was treated with 2 N HCl in Et2O (0.30 mL, 0.600 mmol) at 0 °C and the mixture was 
stirred for 4 h and was concentrated by Argon flow to afford 49 (0.0093 g, 99%) as a white solid: 
1H NMR (MeOD) δ 8.80 (d, 1 H, J = 6.0 Hz), 8.58 (d, 1 H, J = 6.0 Hz), 8.27 (s, 1 H), 7.99 (dd, 1 
H, J = 6.0, 6.0 Hz), 6.07 (d, 1 H, J = 6.9 Hz), 3.70 ~ 3.40 (m, 6 H), 2.89 (m, 1 H), 1.04 (m, 2 H), 
0.97 (d, 1 H, J = 5.1 Hz). 
 
Procedure for analyses of enantiomeric excess of epoxide 42 via chiral SFC. 
SFC was performed on a Metter Toledo-MiniGram instrument with a CHIRALPAK IB column 
(250 x 4.6 mm) at room temperature using a Berger KNR-2501 Detector (220 nm). Samples 
were prepared by dissolving 1.0 – 2.0 mg of the pure compounds in 1.0 – 2.0 mL of MeOH 
(HPLC grade). Ten microliter (10 µL) of the solution was injected for analyses. HPLC grade 2-
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propanyol (5%) was used for the elution. The flow rate was 1.5 mL/min and the outlet pressure 
was 100 bar. The retention time of R-isomer is 12.09 min and the retention time of S-isomer is 
12.89 min.  
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APPENDIX A X-ray data of 8B 
Table 9 Crystal data and structure refinement for 8b 
Identification code  ting127s 
Empirical formula  C17 H20 F8 N2 O2 S 
Formula weight  468.41 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C 2/c 
Unit cell dimensions a = 21.098(3) Å a= 90°. 
 b = 23.909(3) Å b= 109.994(3)°. 
 c = 17.404(2) Å g = 90°. 
Volume 8250.2(18) Å3 
Z 16 
Density (calculated) 1.508 Mg/m3 
Absorption coefficient 0.244 mm-1 
F(000) 3840 
Crystal size 0.24 x 0.14 x 0.14 mm3 
Theta range for data collection 1.57 to 27.50°. 
Index ranges -27<=h<=27, -31<=k<=31, -22<=l<=22 
Reflections collected 39637 
Independent reflections 9475 [R(int) = 0.0637] 
Completeness to theta = 27.50° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9667 and 0.9438 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 9475 / 0 / 567 
Goodness-of-fit on F2 1.006 
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Final R indices [I>2sigma(I)] R1 = 0.0551, wR2 = 0.1342 
R indices (all data) R1 = 0.0900, wR2 = 0.1508 
Largest diff. peak and hole 0.405 and -0.269 e.Å-3 
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Table 10  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) for 8b.  U(eq) is 
defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
S(1) 3595(1) 1264(1) 6519(1) 51(1) 
O(1) 5508(1) -1763(1) 6530(1) 43(1) 
N(1) 5644(1) 324(1) 6168(1) 39(1) 
F(1) 2928(1) 1003(1) 5918(1) 78(1) 
C(1) 5047(1) 230(1) 6296(1) 34(1) 
N(2) 4088(1) -2061(1) 5785(1) 38(1) 
C(2) 4676(1) 709(1) 6358(1) 37(1) 
F(2) 3421(1) 1033(1) 7268(1) 78(1) 
S(2) 1378(1) 1295(1) 2761(1) 53(1) 
O(2) -346(1) -1787(1) 1136(1) 43(1) 
F(3) 3177(1) 1806(1) 6555(1) 77(1) 
C(3) 4075(1) 646(1) 6477(1) 38(1) 
N(3) -573(1) 288(1) 613(1) 39(1) 
O(3) 6369(1) -1672(1) 8062(1) 55(1) 
F(4) 4235(1) 1567(1) 7125(1) 75(1) 
C(4) 3822(1) 115(1) 6559(2) 41(1) 
N(4) 1086(1) -2044(1) 1756(1) 39(1) 
O(4) 1346(1) -1651(1) 3263(1) 55(1) 
F(5) 3741(1) 1539(1) 5776(1) 76(1) 
C(5) 4181(1) -352(1) 6514(1) 40(1) 
C(6) 4802(1) -311(1) 6368(1) 34(1) 
F(6) 6633(1) 444(1) 5542(1) 86(1) 
C(7) 5200(1) -779(1) 6299(1) 35(1) 
F(7) 7127(1) 102(1) 6713(1) 87(1) 
C(8) 5796(1) -676(1) 6173(1) 39(1) 
F(8) 6874(1) -420(1) 5675(1) 82(1) 
C(9) 5988(1) -121(1) 6110(1) 38(1) 
F(9) 2074(1) 1027(1) 2806(1) 65(1) 
C(10) 4975(1) -1372(1) 6372(1) 37(1) 
F(10) 1496(1) 1075(1) 3651(1) 77(1) 
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C(11) 4414(1) -1561(1) 5588(1) 38(1) 
F(11) 1779(1) 1839(1) 3159(1) 80(1) 
C(12) 3541(1) -2273(1) 5064(2) 52(1) 
F(12) 719(1) 1598(1) 2754(1) 91(1) 
C(13) 3759(2) -2378(1) 4333(2) 57(1) 
F(13) 1308(1) 1548(1) 1901(1) 80(1) 
C(14) 4084(2) -1862(1) 4127(2) 62(1) 
F(14) -1594(1) 380(1) -814(1) 82(1) 
C(15) 4658(2) -1658(1) 4877(2) 54(1) 
F(15) -2048(1) -60(1) -89(1) 96(1) 
C(16) 6652(1) 2(1) 6003(2) 49(1) 
F(16) -1711(1) -489(1) -933(1) 89(1) 
C(17) 14(1) 221(1) 1263(1) 36(1) 
C(18) 355(1) 711(1) 1636(2) 41(1) 
C(19) 926(1) 667(1) 2303(1) 39(1) 
C(20) 1177(1) 146(1) 2638(1) 39(1) 
C(21) 855(1) -332(1) 2284(1) 39(1) 
C(22) 270(1) -313(1) 1576(1) 34(1) 
C(23) -86(1) -794(1) 1166(1) 34(1) 
C(24) -666(1) -716(1) 519(1) 39(1) 
C(25) -886(1) -168(1) 279(1) 37(1) 
C(26) 161(1) -1378(1) 1462(1) 35(1) 
C(27) 781(1) -1553(1) 1247(1) 37(1) 
C(28) 1691(1) -2244(1) 1592(2) 53(1) 
C(29) 1561(1) -2369(1) 705(2) 58(1) 
C(30) 1260(2) -1866(1) 179(2) 60(1) 
C(31) 629(1) -1658(1) 340(2) 48(1) 
C(32) -1561(1) -78(1) -388(2) 47(1) 
C(33) 7056(2) -1556(2) 8373(2) 90(1) 
C(34) 2008(2) -1476(2) 3621(2) 85(1) 
________________________________________________________________________________ 
 77 
 Table 11  Bond lengths [Å] and angles [°] for  8b. 
_____________________________________________________  
S(1)-F(1)  1.5666(18) 
S(1)-F(2)  1.5708(18) 
S(1)-F(5)  1.5718(18) 
S(1)-F(4)  1.5767(18) 
S(1)-F(3)  1.5792(16) 
S(1)-C(3)  1.807(2) 
O(1)-C(10)  1.416(3) 
O(1)-H(1O)  0.78(3) 
N(1)-C(9)  1.311(3) 
N(1)-C(1)  1.370(3) 
C(1)-C(2)  1.411(3) 
C(1)-C(6)  1.416(3) 
N(2)-C(12)  1.474(3) 
N(2)-C(11)  1.476(3) 
N(2)-H(2N)  0.84(2) 
C(2)-C(3)  1.361(3) 
C(2)-H(2A)  0.9400 
S(2)-F(12)  1.5640(19) 
S(2)-F(10)  1.5732(18) 
S(2)-F(13)  1.5739(19) 
S(2)-F(11)  1.5766(16) 
S(2)-F(9)  1.5781(17) 
S(2)-C(19)  1.811(2) 
O(2)-C(26)  1.416(3) 
O(2)-H(2O)  0.79(3) 
C(3)-C(4)  1.404(3) 
N(3)-C(25)  1.303(3) 
N(3)-C(17)  1.371(3) 
O(3)-C(33)  1.391(3) 
O(3)-H(3O)  0.79(3) 
C(4)-C(5)  1.368(3) 
C(4)-H(4A)  0.9400 
N(4)-C(27)  1.478(3) 
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N(4)-C(28)  1.481(3) 
N(4)-H(4N)  0.81(2) 
O(4)-C(34)  1.387(3) 
O(4)-H(4O)  0.88(3) 
C(5)-C(6)  1.419(3) 
C(5)-H(5A)  0.9400 
C(6)-C(7)  1.429(3) 
F(6)-C(16)  1.320(3) 
C(7)-C(8)  1.370(3) 
C(7)-C(10)  1.513(3) 
F(7)-C(16)  1.321(3) 
C(8)-C(9)  1.403(3) 
C(8)-H(8A)  0.9400 
F(8)-C(16)  1.321(3) 
C(9)-C(16)  1.502(3) 
C(10)-C(11)  1.538(3) 
C(10)-H(10A)  0.9900 
C(11)-C(15)  1.512(4) 
C(11)-H(11A)  0.9900 
C(12)-C(13)  1.515(4) 
C(12)-H(12A)  0.9800 
C(12)-H(12B)  0.9800 
C(13)-C(14)  1.515(4) 
C(13)-H(13A)  0.9800 
C(13)-H(13B)  0.9800 
C(14)-C(15)  1.525(4) 
C(14)-H(14A)  0.9800 
C(14)-H(14B)  0.9800 
F(14)-C(32)  1.311(3) 
C(15)-H(15A)  0.9800 
C(15)-H(15B)  0.9800 
F(15)-C(32)  1.302(3) 
F(16)-C(32)  1.325(3) 
C(17)-C(18)  1.411(3) 
C(17)-C(22)  1.420(3) 
C(18)-C(19)  1.362(3) 
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C(18)-H(18A)  0.9400 
C(19)-C(20)  1.399(3) 
C(20)-C(21)  1.363(3) 
C(20)-H(20A)  0.9400 
C(21)-C(22)  1.417(3) 
C(21)-H(21A)  0.9400 
C(22)-C(23)  1.423(3) 
C(23)-C(24)  1.364(3) 
C(23)-C(26)  1.517(3) 
C(24)-C(25)  1.405(3) 
C(24)-H(24A)  0.9400 
C(25)-C(32)  1.514(3) 
C(26)-C(27)  1.538(3) 
C(26)-H(26A)  0.9900 
C(27)-C(31)  1.521(3) 
C(27)-H(27A)  0.9900 
C(28)-C(29)  1.502(4) 
C(28)-H(28A)  0.9800 
C(28)-H(28B)  0.9800 
C(29)-C(30)  1.512(4) 
C(29)-H(29A)  0.9800 
C(29)-H(29B)  0.9800 
C(30)-C(31)  1.534(4) 
C(30)-H(30A)  0.9800 
C(30)-H(30B)  0.9800 
C(31)-H(31A)  0.9800 
C(31)-H(31B)  0.9800 
C(33)-H(33A)  0.9700 
C(33)-H(33B)  0.9700 
C(33)-H(33C)  0.9700 
C(34)-H(34A)  0.9700 
C(34)-H(34B)  0.9700 
C(34)-H(34C)  0.9700 
 
F(1)-S(1)-F(2) 90.17(12) 
F(1)-S(1)-F(5) 90.11(11) 
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F(2)-S(1)-F(5) 175.57(9) 
F(1)-S(1)-F(4) 175.81(9) 
F(2)-S(1)-F(4) 89.69(11) 
F(5)-S(1)-F(4) 89.71(11) 
F(1)-S(1)-F(3) 88.12(9) 
F(2)-S(1)-F(3) 87.89(10) 
F(5)-S(1)-F(3) 87.70(9) 
F(4)-S(1)-F(3) 87.69(9) 
F(1)-S(1)-C(3) 92.00(10) 
F(2)-S(1)-C(3) 92.24(10) 
F(5)-S(1)-C(3) 92.17(10) 
F(4)-S(1)-C(3) 92.19(10) 
F(3)-S(1)-C(3) 179.83(12) 
C(10)-O(1)-H(1O) 110(2) 
C(9)-N(1)-C(1) 116.44(19) 
N(1)-C(1)-C(2) 116.47(19) 
N(1)-C(1)-C(6) 123.22(19) 
C(2)-C(1)-C(6) 120.31(19) 
C(12)-N(2)-C(11) 111.81(19) 
C(12)-N(2)-H(2N) 105.0(16) 
C(11)-N(2)-H(2N) 109.8(16) 
C(3)-C(2)-C(1) 119.6(2) 
C(3)-C(2)-H(2A) 120.2 
C(1)-C(2)-H(2A) 120.2 
F(12)-S(2)-F(10) 90.16(12) 
F(12)-S(2)-F(13) 91.13(12) 
F(10)-S(2)-F(13) 175.52(10) 
F(12)-S(2)-F(11) 87.85(10) 
F(10)-S(2)-F(11) 87.85(10) 
F(13)-S(2)-F(11) 87.91(10) 
F(12)-S(2)-F(9) 175.69(9) 
F(10)-S(2)-F(9) 89.15(10) 
F(13)-S(2)-F(9) 89.24(11) 
F(11)-S(2)-F(9) 87.87(10) 
F(12)-S(2)-C(19) 92.75(10) 
F(10)-S(2)-C(19) 92.19(10) 
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F(13)-S(2)-C(19) 92.03(10) 
F(11)-S(2)-C(19) 179.39(12) 
F(9)-S(2)-C(19) 91.52(10) 
C(26)-O(2)-H(2O) 106(2) 
C(2)-C(3)-C(4) 121.4(2) 
C(2)-C(3)-S(1) 118.75(17) 
C(4)-C(3)-S(1) 119.87(17) 
C(25)-N(3)-C(17) 116.51(18) 
C(33)-O(3)-H(3O) 110(2) 
C(5)-C(4)-C(3) 119.7(2) 
C(5)-C(4)-H(4A) 120.2 
C(3)-C(4)-H(4A) 120.2 
C(27)-N(4)-C(28) 111.67(19) 
C(27)-N(4)-H(4N) 107.8(16) 
C(28)-N(4)-H(4N) 105.7(16) 
C(34)-O(4)-H(4O) 112.3(18) 
C(4)-C(5)-C(6) 121.1(2) 
C(4)-C(5)-H(5A) 119.4 
C(6)-C(5)-H(5A) 119.4 
C(1)-C(6)-C(5) 117.85(19) 
C(1)-C(6)-C(7) 117.69(19) 
C(5)-C(6)-C(7) 124.5(2) 
C(8)-C(7)-C(6) 118.11(19) 
C(8)-C(7)-C(10) 120.8(2) 
C(6)-C(7)-C(10) 121.05(19) 
C(7)-C(8)-C(9) 119.3(2) 
C(7)-C(8)-H(8A) 120.4 
C(9)-C(8)-H(8A) 120.4 
N(1)-C(9)-C(8) 125.3(2) 
N(1)-C(9)-C(16) 114.6(2) 
C(8)-C(9)-C(16) 120.1(2) 
O(1)-C(10)-C(7) 112.59(18) 
O(1)-C(10)-C(11) 107.34(17) 
C(7)-C(10)-C(11) 111.69(18) 
O(1)-C(10)-H(10A) 108.4 
C(7)-C(10)-H(10A) 108.4 
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C(11)-C(10)-H(10A) 108.4 
N(2)-C(11)-C(15) 112.48(18) 
N(2)-C(11)-C(10) 108.08(17) 
C(15)-C(11)-C(10) 113.3(2) 
N(2)-C(11)-H(11A) 107.6 
C(15)-C(11)-H(11A) 107.6 
C(10)-C(11)-H(11A) 107.6 
N(2)-C(12)-C(13) 113.5(2) 
N(2)-C(12)-H(12A) 108.9 
C(13)-C(12)-H(12A) 108.9 
N(2)-C(12)-H(12B) 108.9 
C(13)-C(12)-H(12B) 108.9 
H(12A)-C(12)-H(12B) 107.7 
C(14)-C(13)-C(12) 110.8(2) 
C(14)-C(13)-H(13A) 109.5 
C(12)-C(13)-H(13A) 109.5 
C(14)-C(13)-H(13B) 109.5 
C(12)-C(13)-H(13B) 109.5 
H(13A)-C(13)-H(13B) 108.1 
C(13)-C(14)-C(15) 110.5(2) 
C(13)-C(14)-H(14A) 109.6 
C(15)-C(14)-H(14A) 109.6 
C(13)-C(14)-H(14B) 109.6 
C(15)-C(14)-H(14B) 109.6 
H(14A)-C(14)-H(14B) 108.1 
C(11)-C(15)-C(14) 110.9(2) 
C(11)-C(15)-H(15A) 109.5 
C(14)-C(15)-H(15A) 109.5 
C(11)-C(15)-H(15B) 109.5 
C(14)-C(15)-H(15B) 109.5 
H(15A)-C(15)-H(15B) 108.1 
F(6)-C(16)-F(7) 106.2(2) 
F(6)-C(16)-F(8) 106.8(2) 
F(7)-C(16)-F(8) 105.9(2) 
F(6)-C(16)-C(9) 113.3(2) 
F(7)-C(16)-C(9) 111.2(2) 
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F(8)-C(16)-C(9) 112.9(2) 
N(3)-C(17)-C(18) 117.23(19) 
N(3)-C(17)-C(22) 122.6(2) 
C(18)-C(17)-C(22) 120.1(2) 
C(19)-C(18)-C(17) 119.5(2) 
C(19)-C(18)-H(18A) 120.2 
C(17)-C(18)-H(18A) 120.2 
C(18)-C(19)-C(20) 121.4(2) 
C(18)-C(19)-S(2) 119.41(18) 
C(20)-C(19)-S(2) 119.15(18) 
C(21)-C(20)-C(19) 119.9(2) 
C(21)-C(20)-H(20A) 120.0 
C(19)-C(20)-H(20A) 120.0 
C(20)-C(21)-C(22) 121.2(2) 
C(20)-C(21)-H(21A) 119.4 
C(22)-C(21)-H(21A) 119.4 
C(21)-C(22)-C(17) 117.8(2) 
C(21)-C(22)-C(23) 124.3(2) 
C(17)-C(22)-C(23) 117.9(2) 
C(24)-C(23)-C(22) 118.3(2) 
C(24)-C(23)-C(26) 120.82(19) 
C(22)-C(23)-C(26) 120.85(19) 
C(23)-C(24)-C(25) 119.0(2) 
C(23)-C(24)-H(24A) 120.5 
C(25)-C(24)-H(24A) 120.5 
N(3)-C(25)-C(24) 125.6(2) 
N(3)-C(25)-C(32) 115.0(2) 
C(24)-C(25)-C(32) 119.2(2) 
O(2)-C(26)-C(23) 112.05(18) 
O(2)-C(26)-C(27) 107.61(17) 
C(23)-C(26)-C(27) 112.89(18) 
O(2)-C(26)-H(26A) 108.0 
C(23)-C(26)-H(26A) 108.0 
C(27)-C(26)-H(26A) 108.0 
N(4)-C(27)-C(31) 112.62(18) 
N(4)-C(27)-C(26) 107.64(17) 
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C(31)-C(27)-C(26) 113.76(19) 
N(4)-C(27)-H(27A) 107.5 
C(31)-C(27)-H(27A) 107.5 
C(26)-C(27)-H(27A) 107.5 
N(4)-C(28)-C(29) 113.3(2) 
N(4)-C(28)-H(28A) 108.9 
C(29)-C(28)-H(28A) 108.9 
N(4)-C(28)-H(28B) 108.9 
C(29)-C(28)-H(28B) 108.9 
H(28A)-C(28)-H(28B) 107.7 
C(28)-C(29)-C(30) 110.8(2) 
C(28)-C(29)-H(29A) 109.5 
C(30)-C(29)-H(29A) 109.5 
C(28)-C(29)-H(29B) 109.5 
C(30)-C(29)-H(29B) 109.5 
H(29A)-C(29)-H(29B) 108.1 
C(29)-C(30)-C(31) 111.0(2) 
C(29)-C(30)-H(30A) 109.4 
C(31)-C(30)-H(30A) 109.4 
C(29)-C(30)-H(30B) 109.4 
C(31)-C(30)-H(30B) 109.4 
H(30A)-C(30)-H(30B) 108.0 
C(27)-C(31)-C(30) 110.8(2) 
C(27)-C(31)-H(31A) 109.5 
C(30)-C(31)-H(31A) 109.5 
C(27)-C(31)-H(31B) 109.5 
C(30)-C(31)-H(31B) 109.5 
H(31A)-C(31)-H(31B) 108.1 
F(15)-C(32)-F(14) 107.6(2) 
F(15)-C(32)-F(16) 106.3(2) 
F(14)-C(32)-F(16) 105.1(2) 
F(15)-C(32)-C(25) 111.2(2) 
F(14)-C(32)-C(25) 114.0(2) 
F(16)-C(32)-C(25) 112.1(2) 
O(3)-C(33)-H(33A) 109.5 
O(3)-C(33)-H(33B) 109.5 
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H(33A)-C(33)-H(33B) 109.5 
O(3)-C(33)-H(33C) 109.5 
H(33A)-C(33)-H(33C) 109.5 
H(33B)-C(33)-H(33C) 109.5 
O(4)-C(34)-H(34A) 109.5 
O(4)-C(34)-H(34B) 109.5 
H(34A)-C(34)-H(34B) 109.5 
O(4)-C(34)-H(34C) 109.5 
H(34A)-C(34)-H(34C) 109.5 
H(34B)-C(34)-H(34C) 109.5 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 12   Anisotropic displacement parameters  (Å2x 103) for 8b.  The anisotropic displacement factor exponent 
takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S(1) 45(1)  42(1) 71(1)  -2(1) 27(1)  10(1) 
O(1) 45(1)  32(1) 47(1)  3(1) 10(1)  8(1) 
N(1) 35(1)  35(1) 51(1)  1(1) 19(1)  0(1) 
F(1) 40(1)  69(1) 113(2)  -11(1) 10(1)  14(1) 
C(1) 33(1)  34(1) 37(1)  -1(1) 13(1)  0(1) 
N(2) 34(1)  31(1) 45(1)  3(1) 7(1)  3(1) 
C(2) 37(1)  32(1) 45(1)  1(1) 16(1)  2(1) 
F(2) 96(1)  70(1) 96(1)  3(1) 67(1)  22(1) 
S(2) 53(1)  40(1) 65(1)  -9(1) 19(1)  -14(1) 
O(2) 38(1)  30(1) 65(1)  -4(1) 22(1)  -6(1) 
F(3) 64(1)  52(1) 127(2)  -4(1) 48(1)  21(1) 
C(3) 37(1)  35(1) 43(1)  -3(1) 15(1)  8(1) 
N(3) 38(1)  33(1) 45(1)  4(1) 14(1)  5(1) 
O(3) 38(1)  75(1) 52(1)  7(1) 16(1)  -2(1) 
F(4) 60(1)  54(1) 106(1)  -31(1) 24(1)  4(1) 
C(4) 33(1)  42(1) 52(1)  0(1) 19(1)  1(1) 
N(4) 32(1)  32(1) 56(1)  4(1) 17(1)  0(1) 
O(4) 38(1)  71(1) 56(1)  -6(1) 14(1)  -4(1) 
F(5) 89(1)  57(1) 96(1)  29(1) 51(1)  32(1) 
C(5) 38(1)  37(1) 47(1)  0(1) 17(1)  -3(1) 
C(6) 34(1)  32(1) 35(1)  0(1) 11(1)  0(1) 
F(6) 60(1)  79(1) 138(2)  50(1) 58(1)  15(1) 
C(7) 35(1)  32(1) 36(1)  0(1) 11(1)  1(1) 
F(7) 38(1)  126(2) 93(1)  -14(1) 18(1)  -9(1) 
C(8) 37(1)  34(1) 48(1)  0(1) 16(1)  6(1) 
F(8) 72(1)  68(1) 134(2)  -16(1) 72(1)  0(1) 
C(9) 35(1)  36(1) 44(1)  0(1) 16(1)  2(1) 
F(9) 45(1)  62(1) 87(1)  -5(1) 21(1)  -16(1) 
C(10) 40(1)  31(1) 39(1)  3(1) 13(1)  4(1) 
F(10) 104(1)  73(1) 57(1)  -21(1) 32(1)  -37(1) 
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C(11) 44(1)  28(1) 39(1)  4(1) 10(1)  4(1) 
F(11) 80(1)  51(1) 98(1)  -19(1) 17(1)  -29(1) 
C(12) 42(1)  47(1) 56(2)  -2(1) 1(1)  0(1) 
F(12) 67(1)  51(1) 152(2)  -44(1) 35(1)  -5(1) 
C(13) 58(2)  51(2) 49(2)  -12(1) 0(1)  1(1) 
F(13) 95(1)  53(1) 76(1)  16(1) 12(1)  -28(1) 
C(14) 85(2)  60(2) 38(2)  -2(1) 16(1)  3(2) 
F(14) 61(1)  80(1) 82(1)  36(1) -7(1)  -2(1) 
C(15) 74(2)  49(2) 40(1)  0(1) 23(1)  -8(1) 
F(15) 38(1)  175(2) 77(1)  26(1) 23(1)  22(1) 
C(16) 37(1)  45(1) 70(2)  4(1) 24(1)  4(1) 
F(16) 70(1)  81(1) 80(1)  -23(1) -20(1)  17(1) 
C(17) 36(1)  34(1) 42(1)  1(1) 18(1)  3(1) 
C(18) 44(1)  30(1) 52(1)  2(1) 21(1)  2(1) 
C(19) 39(1)  35(1) 45(1)  -5(1) 18(1)  -7(1) 
C(20) 34(1)  41(1) 41(1)  0(1) 12(1)  -4(1) 
C(21) 37(1)  35(1) 44(1)  4(1) 15(1)  1(1) 
C(22) 31(1)  31(1) 43(1)  0(1) 16(1)  2(1) 
C(23) 33(1)  33(1) 41(1)  0(1) 17(1)  -1(1) 
C(24) 36(1)  34(1) 45(1)  -4(1) 13(1)  -3(1) 
C(25) 33(1)  38(1) 42(1)  2(1) 14(1)  4(1) 
C(26) 31(1)  30(1) 45(1)  1(1) 13(1)  -2(1) 
C(27) 37(1)  28(1) 49(1)  1(1) 18(1)  -1(1) 
C(28) 39(1)  48(1) 78(2)  5(1) 29(1)  8(1) 
C(29) 52(2)  54(2) 80(2)  -6(1) 38(2)  2(1) 
C(30) 68(2)  60(2) 67(2)  -5(1) 43(2)  -6(1) 
C(31) 54(2)  46(1) 48(2)  3(1) 22(1)  4(1) 
C(32) 36(1)  47(1) 54(2)  3(1) 11(1)  3(1) 
C(33) 43(2)  142(4) 87(3)  4(2) 22(2)  -15(2) 
C(34) 39(2)  118(3) 84(2)  -5(2) 2(2)  0(2) 
______________________________________________________________________________ 
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 Table 13  Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for 8b. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1O) 5759(15) -1726(12) 6972(19) 63(10) 
H(2N) 4367(12) -2323(10) 5927(14) 35(6) 
H(2A) 4842 1068 6317 45 
H(2O) -643(15) -1713(11) 1300(17) 53(9) 
H(3O) 6257(16) -1839(13) 8390(20) 74(11) 
H(4A) 3407 81 6645 49 
H(4N) 815(12) -2299(10) 1622(14) 34(6) 
H(4O) 1279(13) -1827(12) 2801(18) 57(9) 
H(5A) 4015 -707 6581 48 
H(8A) 6072 -974 6129 47 
H(10A) 4798 -1386 6830 44 
H(11A) 4071 -1259 5428 45 
H(12A) 3170 -2001 4911 63 
H(12B) 3369 -2622 5211 63 
H(13A) 4080 -2690 4453 69 
H(13B) 3365 -2483 3861 69 
H(14A) 3746 -1565 3934 75 
H(14B) 4260 -1949 3688 75 
H(15A) 5021 -1936 5031 64 
H(15B) 4841 -1308 4746 64 
H(18A) 188 1064 1427 49 
H(20A) 1566 126 3107 47 
H(21A) 1026 -680 2514 46 
H(24A) -916 -1024 238 47 
H(26A) 288 -1383 2065 42 
H(27A) 1112 -1244 1411 45 
H(28A) 1858 -2584 1912 63 
H(28B) 2046 -1960 1776 63 
H(29A) 1251 -2686 534 69 
H(29B) 1986 -2472 629 69 
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H(30A) 1140 -1967 -399 71 
H(30B) 1595 -1565 297 71 
H(31A) 470 -1311 35 58 
H(31B) 270 -1938 146 58 
H(33A) 7176 -1313 7998 136 
H(33B) 7309 -1902 8440 136 
H(33C) 7163 -1372 8899 136 
H(34A) 2125 -1227 3250 128 
H(34B) 2305 -1798 3738 128 
H(34C) 2058 -1279 4126 128 
________________________________________________________________________________  
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APPENDIX B X-ray data of 27 
Table 14  Crystal data and structure refinement for 27 
Identification code  tt18157s 
Empirical formula  C16 H16 F8 N2 O S 
Formula weight  436.37 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Tetragonal 
Space group  P4(2)/n 
Unit cell dimensions a = 20.557(4) Å a= 90°. 
 b = 20.557(4) Å b= 90°. 
 c = 8.708(2) Å g= 90°. 
Volume 3679.9(14) Å3 
Z 8 
Density (calculated) 1.575 Mg/m3 
Absorption coefficient 0.263 mm-1 
F(000) 1776 
Crystal size 0.25 x 0.16 x 0.09 mm3 
Theta range for data collection 1.98 to 25.00°. 
Index ranges -24<=h<=24, -24<=k<=24, -10<=l<=10 
Reflections collected 28259 
Independent reflections 3245 [R(int) = 0.0878] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9767 and 0.9372 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3245 / 1 / 316 
Goodness-of-fit on F2 0.946 
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Final R indices [I>2sigma(I)] R1 = 0.0464, wR2 = 0.1153 
R indices (all data) R1 = 0.0801, wR2 = 0.1300 
Largest diff. peak and hole 0.273 and -0.159 e.Å-3 
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Table 15  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) for 27.  U(eq) 
is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
S 1273(1) 6909(1) 343(1) 62(1) 
O 1478(1) 3462(1) -3137(3) 58(1) 
N(1) 764(1) 5686(1) -1410(2) 48(1) 
C(1) 1399(1) 5641(1) -981(3) 43(1) 
F(1) 908(1) 7566(1) 785(2) 90(1) 
N(2) 2736(1) 3635(1) -4426(3) 60(1) 
F(2) 1562(1) 6907(1) 2021(2) 89(1) 
C(2) 1699(1) 6166(1) -157(3) 48(1) 
F(3) 1864(1) 7345(1) -205(2) 80(1) 
C(3) 2338(1) 6122(2) 274(3) 53(1) 
F(4) 963(1) 6974(1) -1305(2) 66(1) 
C(4) 2710(1) 5571(2) -72(3) 53(1) 
F(5) 657(1) 6533(1) 943(2) 71(1) 
C(5) 2445(1) 5073(2) -869(3) 48(1) 
C(6) 1785(1) 5088(1) -1347(3) 41(1) 
F(6) -430(1) 4782(1) -3371(3) 94(1) 
F(7) -270(1) 5802(1) -3495(2) 87(1) 
C(7) 1490(1) 4574(1) -2190(3) 43(1) 
F(8) -572(1) 5372(1) -1398(2) 82(1) 
C(8) 845(1) 4627(1) -2560(3) 46(1) 
C(9) 512(1) 5190(1) -2151(3) 46(1) 
C(10) -190(1) 5283(2) -2602(4) 59(1) 
C(11) 1878(1) 3995(1) -2732(3) 47(1) 
C(12) 2291(1) 4174(1) -4137(3) 46(1) 
C(13) 1884(2) 4347(2) -5544(3) 52(1) 
C(14) 2300(2) 4452(2) -6962(4) 64(1) 
C(15) 2763(2) 3885(2) -7211(4) 76(1) 
C(16) 3152(2) 3757(2) -5779(4) 80(1) 
________________________________________________________________________________ 
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 Table 16   Bond lengths [Å] and angles [°] for 27. 
_____________________________________________________  
S-F(5)  1.5730(18) 
S-F(4)  1.5760(19) 
S-F(2)  1.577(2) 
S-F(3)  1.5827(19) 
S-F(1)  1.5929(19) 
S-C(2)  1.812(3) 
O-C(11)  1.416(3) 
O-H(1O)  0.89(4) 
N(1)-C(9)  1.313(3) 
N(1)-C(1)  1.363(3) 
C(1)-C(6)  1.422(4) 
C(1)-C(2)  1.435(4) 
N(2)-C(12)  1.458(3) 
N(2)-C(16)  1.477(4) 
N(2)-H(2N)  0.860(10) 
C(2)-C(3)  1.368(4) 
C(3)-C(4)  1.401(4) 
C(3)-H(3)  0.89(3) 
C(4)-C(5)  1.351(4) 
C(4)-H(4)  0.95(3) 
C(5)-C(6)  1.420(4) 
C(5)-H(5)  0.92(2) 
C(6)-C(7)  1.422(4) 
F(6)-C(10)  1.323(3) 
F(7)-C(10)  1.332(4) 
C(7)-C(8)  1.369(4) 
C(7)-C(11)  1.509(4) 
F(8)-C(10)  1.322(3) 
C(8)-C(9)  1.391(4) 
C(8)-H(8)  0.96(3) 
C(9)-C(10)  1.507(4) 
C(11)-C(12)  1.533(4) 
C(11)-H(11)  0.99(2) 
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C(12)-C(13)  1.525(4) 
C(12)-H(12)  0.92(2) 
C(13)-C(14)  1.517(4) 
C(13)-H(13A)  0.95(3) 
C(13)-H(13B)  0.98(3) 
C(14)-C(15)  1.520(5) 
C(14)-H(14A)  0.92(3) 
C(14)-H(14B)  1.04(4) 
C(15)-C(16)  1.504(5) 
C(15)-H(15A)  1.04(3) 
C(15)-H(15B)  0.94(4) 
C(16)-H(16A)  0.99(4) 
C(16)-H(16B)  1.02(3) 
 
F(5)-S-F(4) 91.07(10) 
F(5)-S-F(2) 89.66(11) 
F(4)-S-F(2) 174.85(11) 
F(5)-S-F(3) 174.78(10) 
F(4)-S-F(3) 89.27(11) 
F(2)-S-F(3) 89.55(12) 
F(5)-S-F(1) 87.45(10) 
F(4)-S-F(1) 87.52(11) 
F(2)-S-F(1) 87.43(12) 
F(3)-S-F(1) 87.37(10) 
F(5)-S-C(2) 93.21(11) 
F(4)-S-C(2) 92.82(11) 
F(2)-S-C(2) 92.22(11) 
F(3)-S-C(2) 91.97(11) 
F(1)-S-C(2) 179.25(12) 
C(11)-O-H(1O) 105(2) 
C(9)-N(1)-C(1) 117.4(2) 
N(1)-C(1)-C(6) 121.9(2) 
N(1)-C(1)-C(2) 119.9(2) 
C(6)-C(1)-C(2) 118.3(2) 
C(12)-N(2)-C(16) 111.8(3) 
C(12)-N(2)-H(2N) 110(2) 
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C(16)-N(2)-H(2N) 109(2) 
C(3)-C(2)-C(1) 120.0(3) 
C(3)-C(2)-S 116.9(2) 
C(1)-C(2)-S 123.07(19) 
C(2)-C(3)-C(4) 121.2(3) 
C(2)-C(3)-H(3) 117.1(18) 
C(4)-C(3)-H(3) 121.7(18) 
C(5)-C(4)-C(3) 120.3(3) 
C(5)-C(4)-H(4) 121.4(16) 
C(3)-C(4)-H(4) 118.3(16) 
C(4)-C(5)-C(6) 121.2(3) 
C(4)-C(5)-H(5) 118.5(15) 
C(6)-C(5)-H(5) 120.3(15) 
C(7)-C(6)-C(5) 122.8(2) 
C(7)-C(6)-C(1) 118.2(2) 
C(5)-C(6)-C(1) 119.0(2) 
C(8)-C(7)-C(6) 118.3(2) 
C(8)-C(7)-C(11) 120.1(2) 
C(6)-C(7)-C(11) 121.5(2) 
C(7)-C(8)-C(9) 118.9(3) 
C(7)-C(8)-H(8) 119.5(15) 
C(9)-C(8)-H(8) 121.6(14) 
N(1)-C(9)-C(8) 125.2(2) 
N(1)-C(9)-C(10) 114.1(2) 
C(8)-C(9)-C(10) 120.7(2) 
F(8)-C(10)-F(6) 106.8(3) 
F(8)-C(10)-F(7) 106.1(2) 
F(6)-C(10)-F(7) 106.4(3) 
F(8)-C(10)-C(9) 112.3(2) 
F(6)-C(10)-C(9) 112.9(3) 
F(7)-C(10)-C(9) 111.8(2) 
O-C(11)-C(7) 112.5(2) 
O-C(11)-C(12) 108.0(2) 
C(7)-C(11)-C(12) 110.7(2) 
O-C(11)-H(11) 109.5(14) 
C(7)-C(11)-H(11) 108.1(14) 
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C(12)-C(11)-H(11) 108.1(14) 
N(2)-C(12)-C(13) 112.5(2) 
N(2)-C(12)-C(11) 107.6(2) 
C(13)-C(12)-C(11) 113.2(2) 
N(2)-C(12)-H(12) 105.5(15) 
C(13)-C(12)-H(12) 105.6(14) 
C(11)-C(12)-H(12) 112.2(14) 
C(14)-C(13)-C(12) 112.2(3) 
C(14)-C(13)-H(13A) 106.3(15) 
C(12)-C(13)-H(13A) 110.4(15) 
C(14)-C(13)-H(13B) 112.1(15) 
C(12)-C(13)-H(13B) 109.2(15) 
H(13A)-C(13)-H(13B) 106(2) 
C(13)-C(14)-C(15) 111.1(3) 
C(13)-C(14)-H(14A) 109(2) 
C(15)-C(14)-H(14A) 108(2) 
C(13)-C(14)-H(14B) 108.0(18) 
C(15)-C(14)-H(14B) 111.3(19) 
H(14A)-C(14)-H(14B) 110(3) 
C(16)-C(15)-C(14) 110.5(3) 
C(16)-C(15)-H(15A) 109.0(17) 
C(14)-C(15)-H(15A) 109.1(17) 
C(16)-C(15)-H(15B) 109(2) 
C(14)-C(15)-H(15B) 108(2) 
H(15A)-C(15)-H(15B) 112(3) 
N(2)-C(16)-C(15) 112.5(3) 
N(2)-C(16)-H(16A) 105(2) 
C(15)-C(16)-H(16A) 111(2) 
N(2)-C(16)-H(16B) 108.6(17) 
C(15)-C(16)-H(16B) 108.3(18) 
H(16A)-C(16)-H(16B) 111(3) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 17 Anisotropic displacement parameters (Å2x 103) for 27.  The anisotropic displacement factor exponent 
takes the form:  -2p2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S 52(1)  69(1) 65(1)  -16(1) 2(1)  -1(1) 
O 57(1)  47(1) 70(1)  11(1) -9(1)  -12(1) 
N(1) 41(1)  64(2) 38(1)  1(1) 2(1)  2(1) 
C(1) 40(1)  59(2) 31(1)  6(1) 3(1)  -2(1) 
F(1) 69(1)  81(1) 120(2)  -38(1) 7(1)  8(1) 
N(2) 49(2)  60(2) 72(2)  -16(1) -9(1)  11(1) 
F(2) 86(1)  115(2) 65(1)  -39(1) -7(1)  6(1) 
C(2) 46(2)  59(2) 38(1)  1(1) 2(1)  -4(1) 
F(3) 58(1)  64(1) 119(2)  -12(1) 6(1)  -6(1) 
C(3) 55(2)  62(2) 41(2)  -2(1) -5(1)  -7(2) 
F(4) 61(1)  69(1) 68(1)  2(1) -4(1)  10(1) 
C(4) 44(2)  69(2) 47(2)  7(1) -11(1)  -5(2) 
F(5) 56(1)  90(1) 67(1)  -17(1) 18(1)  -3(1) 
C(5) 46(2)  56(2) 41(1)  6(1) -3(1)  3(1) 
C(6) 40(1)  53(2) 32(1)  11(1) -1(1)  -2(1) 
F(6) 51(1)  99(2) 130(2)  -43(1) -28(1)  6(1) 
F(7) 59(1)  107(2) 95(1)  24(1) -24(1)  8(1) 
C(7) 41(1)  51(2) 36(1)  12(1) 1(1)  -5(1) 
F(8) 45(1)  125(2) 76(1)  -8(1) 8(1)  8(1) 
C(8) 41(2)  56(2) 41(1)  2(1) -2(1)  -6(1) 
C(9) 37(1)  62(2) 39(1)  -1(1) 2(1)  0(1) 
C(10) 42(2)  71(2) 64(2)  -9(2) -3(1)  1(1) 
C(11) 43(2)  45(2) 52(2)  9(1) -9(1)  -2(1) 
C(12) 40(2)  43(2) 56(2)  -3(1) -2(1)  -1(1) 
C(13) 51(2)  52(2) 51(2)  4(1) 2(1)  4(2) 
C(14) 67(2)  69(2) 55(2)  -5(2) 6(2)  -13(2) 
C(15) 57(2)  104(3) 68(2)  -27(2) 6(2)  -5(2) 
C(16) 51(2)  108(3) 82(2)  -37(2) -2(2)  18(2) 
______________________________________________________________________________ 
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 Table 18   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for 27. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(1O) 1480(17) 3201(17) -2310(50) 88(12) 
H(2N) 2522(14) 3280(9) -4560(40) 72 
H(3) 2507(13) 6462(13) 780(30) 50(8) 
H(4) 3151(13) 5562(12) 250(30) 46(7) 
H(5) 2700(12) 4718(12) -1080(30) 40(7) 
H(8) 636(12) 4281(12) -3100(30) 43(7) 
H(11) 2177(12) 3864(11) -1890(30) 44(7) 
H(12) 2551(11) 4528(11) -3960(20) 36(6) 
H(13A) 1593(12) 4002(13) -5790(30) 48(7) 
H(13B) 1614(13) 4727(13) -5310(30) 52(7) 
H(14A) 2546(16) 4821(16) -6820(30) 76(10) 
H(14B) 1991(17) 4512(16) -7890(40) 90(11) 
H(15A) 2494(15) 3470(15) -7480(30) 70(9) 
H(15B) 3053(17) 3998(16) -8010(40) 85(11) 
H(16A) 3421(17) 3361(17) -5890(40) 86(11) 
H(16B) 3433(15) 4152(16) -5560(30) 73(10) 
________________________________________________________________________________  
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APPENDIX C X-ray data of S-42 
Table 19  Crystal data and structure refinement for S-42. 
Identification code  ting2s 
Empirical formula  C12 H7 F8 N O S 
Formula weight  365.25 
Temperature  203(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21 
Unit cell dimensions a = 9.574(2) Å a = 90°. 
 b = 7.9132(18) Å b = 116.638(4)°. 
 c = 9.783(2) Å g = 90°. 
Volume 662.5(3) Å3 
Z 2 
Density (calculated) 1.831 Mg/m3 
Absorption coefficient 0.344 mm-1 
F(000) 364 
Crystal size 0.25 x 0.10 x 0.08 mm3 
Theta range for data collection 2.33 to 27.49°. 
Index ranges -12<=h<=12, -10<=k<=10, -12<=l<=12 
Reflections collected 6412 
Independent reflections 3017 [R(int) = 0.0466] 
Completeness to theta = 27.49° 99.9 %  
Absorption correction Multi-scan (Sadabs) 
Max. and min. transmission 0.9730 and 0.9190 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3017 / 25 / 266 
Goodness-of-fit on F2 0.987 
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Final R indices [I>2sigma(I)] R1 = 0.0431, wR2 = 0.1048 
R indices (all data) R1 = 0.0540, wR2 = 0.1111 
Absolute structure parameter 0.00(10) 
Largest diff. peak and hole 0.293 and -0.198 e.Å-3 
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Table 20  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 103) for S-42.  U(eq) 
is defined as one third of  the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________  
 x y z U(eq) 
________________________________________________________________________________   
S 3279(1) 1548(1) -181(1) 37(1) 
O -1125(3) 1862(4) 4800(3) 59(1) 
N 2896(3) 1185(3) 2799(2) 37(1) 
F(1) 2754(3) 3146(3) -1280(2) 54(1) 
C(1) 1507(3) 1621(5) 55(3) 33(1) 
F(2) 2466(2) 361(3) -1650(2) 51(1) 
C(2) 125(3) 1864(4) -1237(3) 41(1) 
F(3) 3908(2) -63(2) 851(2) 47(1) 
C(3) -1297(3) 1938(5) -1142(3) 49(1) 
F(4) 4189(2) 2741(3) 1212(2) 49(1) 
C(4) -1329(3) 1811(4) 226(3) 44(1) 
F(5) 4803(2) 1490(4) -435(2) 57(1) 
C(5) 63(3) 1593(4) 1589(3) 33(1) 
F(6) 4185(14) -425(18) 6368(12) 74(4) 
C(6) 91(3) 1475(4) 3050(3) 35(1) 
F(7) 4700(19) 2152(19) 6359(19) 109(5) 
C(7) 1472(3) 1181(4) 4298(3) 40(1) 
F(8) 5520(20) 300(40) 5240(20) 91(5) 
C(8) 2823(3) 1045(4) 4083(3) 41(1) 
C(9) 1518(3) 1468(4) 1514(3) 31(1) 
C(10) -1354(3) 1682(5) 3251(3) 42(1) 
C(11) -1889(5) 378(5) 3947(4) 52(1) 
C(12) 4350(4) 731(6) 5497(4) 60(1) 
F(6') 4630(11) 1710(30) 6605(11) 125(6) 
F(7') 5543(13) 920(40) 5217(15) 115(7) 
F(8') 4430(20) -860(20) 6000(30) 165(7) 
________________________________________________________________________________ 
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 Table 21 Bond lengths [Å] and angles [°] for S-42. 
_____________________________________________________  
S-F(4)  1.5624(19) 
S-F(3)  1.569(2) 
S-F(5)  1.5864(17) 
S-F(1)  1.589(2) 
S-F(2)  1.598(2) 
S-C(1)  1.812(3) 
O-C(11)  1.437(5) 
O-C(10)  1.439(3) 
N-C(8)  1.295(3) 
N-C(9)  1.372(3) 
C(1)-C(2)  1.373(3) 
C(1)-C(9)  1.428(3) 
C(2)-C(3)  1.406(4) 
C(2)-H(2)  0.85(3) 
C(3)-C(4)  1.357(4) 
C(3)-H(3)  0.99(4) 
C(4)-C(5)  1.410(4) 
C(4)-H(4)  0.95(3) 
C(5)-C(6)  1.421(3) 
C(5)-C(9)  1.431(3) 
F(6)-F(8')  0.62(3) 
F(6)-C(12)  1.307(11) 
F(6)-F(6')  1.74(2) 
C(6)-C(7)  1.358(4) 
C(6)-C(10)  1.490(3) 
F(7)-C(12)  1.355(12) 
C(7)-C(8)  1.404(4) 
C(7)-H(7)  0.89(3) 
F(8)-F(7')  0.49(5) 
F(8)-C(12)  1.298(13) 
F(8)-F(8')  1.77(3) 
C(8)-C(12)  1.516(4) 
C(10)-C(11)  1.451(5) 
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C(10)-H(10)  0.84(4) 
C(11)-H(11A)  0.95(4) 
C(11)-H(11B)  0.91(4) 
C(12)-F(6')  1.262(10) 
C(12)-F(7')  1.297(13) 
C(12)-F(8')  1.336(13) 
 
F(4)-S-F(3) 91.55(11) 
F(4)-S-F(5) 87.82(11) 
F(3)-S-F(5) 87.86(12) 
F(4)-S-F(1) 89.60(13) 
F(3)-S-F(1) 174.89(12) 
F(5)-S-F(1) 87.21(12) 
F(4)-S-F(2) 174.98(11) 
F(3)-S-F(2) 89.58(12) 
F(5)-S-F(2) 87.34(11) 
F(1)-S-F(2) 88.86(11) 
F(4)-S-C(1) 93.30(12) 
F(3)-S-C(1) 93.16(13) 
F(5)-S-C(1) 178.46(11) 
F(1)-S-C(1) 91.74(14) 
F(2)-S-C(1) 91.52(12) 
C(11)-O-C(10) 60.6(2) 
C(8)-N-C(9) 117.0(2) 
C(2)-C(1)-C(9) 120.3(2) 
C(2)-C(1)-S 117.3(2) 
C(9)-C(1)-S 122.46(17) 
C(1)-C(2)-C(3) 120.5(3) 
C(1)-C(2)-H(2) 116(2) 
C(3)-C(2)-H(2) 124(2) 
C(4)-C(3)-C(2) 120.8(3) 
C(4)-C(3)-H(3) 126(2) 
C(2)-C(3)-H(3) 113(2) 
C(3)-C(4)-C(5) 120.8(3) 
C(3)-C(4)-H(4) 119.1(19) 
C(5)-C(4)-H(4) 120.0(19) 
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C(4)-C(5)-C(6) 122.9(2) 
C(4)-C(5)-C(9) 119.3(2) 
C(6)-C(5)-C(9) 117.8(2) 
F(8')-F(6)-C(12) 79.2(18) 
F(8')-F(6)-F(6') 119(2) 
C(12)-F(6)-F(6') 46.4(5) 
C(7)-C(6)-C(5) 119.1(2) 
C(7)-C(6)-C(10) 119.2(2) 
C(5)-C(6)-C(10) 121.7(2) 
C(6)-C(7)-C(8) 118.0(2) 
C(6)-C(7)-H(7) 122.7(19) 
C(8)-C(7)-H(7) 119.3(19) 
F(7')-F(8)-C(12) 79(2) 
F(7')-F(8)-F(8') 125(3) 
C(12)-F(8)-F(8') 48.6(9) 
N-C(8)-C(7) 126.4(2) 
N-C(8)-C(12) 116.7(3) 
C(7)-C(8)-C(12) 116.9(2) 
N-C(9)-C(1) 120.2(2) 
N-C(9)-C(5) 121.5(2) 
C(1)-C(9)-C(5) 118.3(2) 
O-C(10)-C(11) 59.6(2) 
O-C(10)-C(6) 116.0(2) 
C(11)-C(10)-C(6) 121.8(3) 
O-C(10)-H(10) 110(3) 
C(11)-C(10)-H(10) 115(3) 
C(6)-C(10)-H(10) 119(2) 
O-C(11)-C(10) 59.8(2) 
O-C(11)-H(11A) 115(2) 
C(10)-C(11)-H(11A) 114(2) 
O-C(11)-H(11B) 116(2) 
C(10)-C(11)-H(11B) 118(2) 
H(11A)-C(11)-H(11B) 119(3) 
F(6')-C(12)-F(8) 117.3(12) 
F(6')-C(12)-F(7') 104.0(10) 
F(8)-C(12)-F(7') 22(2) 
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F(6')-C(12)-F(6) 85.0(9) 
F(8)-C(12)-F(6) 107.9(12) 
F(7')-C(12)-F(6) 126.4(11) 
F(6')-C(12)-F(8') 108.1(11) 
F(8)-C(12)-F(8') 84.7(14) 
F(7')-C(12)-F(8') 105.8(10) 
F(6)-C(12)-F(8') 27.0(14) 
F(6')-C(12)-F(7) 19.1(11) 
F(8)-C(12)-F(7) 110.2(14) 
F(7')-C(12)-F(7) 92.3(12) 
F(6)-C(12)-F(7) 104.1(10) 
F(8')-C(12)-F(7) 126.5(10) 
F(6')-C(12)-C(8) 115.4(6) 
F(8)-C(12)-C(8) 115.5(9) 
F(7')-C(12)-C(8) 111.7(7) 
F(6)-C(12)-C(8) 111.1(6) 
F(8')-C(12)-C(8) 111.2(7) 
F(7)-C(12)-C(8) 107.5(7) 
C(12)-F(6')-F(6) 48.6(6) 
F(8)-F(7')-C(12) 79(3) 
F(6)-F(8')-C(12) 74(2) 
F(6)-F(8')-F(8) 114(3) 
C(12)-F(8')-F(8) 46.7(8) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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Table 22   Anisotropic displacement parameters  (Å2x 103) for S-42.  The anisotropic displacement factor exponent 
takes the form:  -2p 2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
______________________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
______________________________________________________________________________  
S 38(1)  49(1) 27(1)  -3(1) 15(1)  -6(1) 
O 54(1)  84(2) 51(1)  -21(1) 35(1)  -7(1) 
N 32(1)  52(2) 25(1)  2(1) 10(1)  4(1) 
F(1) 62(1)  60(1) 45(1)  13(1) 28(1)  -4(1) 
C(1) 35(1)  35(1) 27(1)  2(1) 11(1)  -1(1) 
F(2) 56(1)  65(1) 35(1)  -16(1) 21(1)  -8(1) 
C(2) 40(1)  51(2) 24(1)  2(1) 8(1)  -2(1) 
F(3) 43(1)  56(1) 45(1)  9(1) 24(1)  11(1) 
C(3) 32(1)  64(2) 35(1)  5(1) 2(1)  1(1) 
F(4) 45(1)  64(1) 38(1)  -14(1) 20(1)  -19(1) 
C(4) 28(1)  55(2) 44(2)  2(2) 12(1)  3(1) 
F(5) 45(1)  87(1) 47(1)  -1(1) 29(1)  -5(1) 
C(5) 29(1)  35(1) 34(1)  0(1) 13(1)  -1(1) 
F(6) 52(4)  124(8) 45(4)  54(4) 19(3)  30(4) 
C(6) 36(1)  36(1) 39(1)  -2(1) 21(1)  -2(1) 
F(7) 77(7)  92(8) 79(8)  -20(5) -37(5)  7(4) 
C(7) 42(2)  50(2) 30(1)  4(1) 19(1)  5(1) 
F(8) 52(6)  190(13) 39(4)  29(5) 27(4)  67(7) 
C(8) 36(1)  55(2) 27(1)  5(1) 12(1)  7(1) 
C(9) 31(1)  34(1) 26(1)  0(1) 10(1)  0(1) 
C(10) 39(1)  51(2) 42(1)  2(2) 22(1)  5(2) 
C(11) 53(2)  67(2) 50(2)  -1(2) 33(2)  -7(2) 
C(12) 39(2)  104(3) 31(2)  10(2) 11(1)  15(2) 
F(6') 43(3)  296(19) 25(3)  -41(6) 4(2)  27(7) 
F(7') 33(3)  270(20) 30(3)  9(7) 2(3)  24(6) 
F(8') 106(8)  160(10) 152(11)  85(9) -11(7)  38(7) 
______________________________________________________________________________ 
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Table 23  Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3) for S-42. 
________________________________________________________________________________  
 x  y  z  U(eq) 
________________________________________________________________________________  
  
H(2) 200(40) 1970(50) -2070(40) 51(10) 
H(3) -2220(40) 2010(50) -2160(40) 60(11) 
H(4) -2300(40) 1940(40) 270(40) 43(9) 
H(7) 1550(30) 1070(40) 5240(40) 33(8) 
H(10) -2060(40) 2360(50) 2680(40) 49(10) 
H(11A) -1270(50) -610(50) 4210(50) 60(12) 
H(11B) -2930(50) 300(50) 3650(40) 50(10) 
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APPENDIX D 1H and 13C NMR spectra of selected compounds 
 109 
 
 110 
 
 111 
 
 112 
 
 113 
 
 114 
 
 115 
 
 116 
 
 117 
 
 118 
 
 119 
 
 120 
 
 121 
 
 122 
 
 123 
 
 124 
 
 125 
 
 126 
 
 127 
 
 128 
 
 129 
 
 130 
 
 131 
 
 132 
 
 133 
 
 134 
 
 135 
 
 136 
 
 137 
 
 138 
 
 139 
 
 140 
 
 141 
 
 142 
 
 143 
 
 144 
 
 145 
 
 146 
 
 147 
 
 148 
 
 149 
BIBLIOGRAPHY 
 
(1) The world health report 1998, World Health Organization, 1998. [Online] 
http://www.who.int/whr/1998/en/index.html 
(2) Wellems, T. E.; Plowe, C. V. J. Infect. Dis. 2001, 184, 770-6. 
(3) Trenholme, C. M.; Williams, R. L.; Desjardins, R. E.; Frischer, H.; Carson, P. E.; 
Rieckmann, K. H.; Canfield, C. J. Science 1975, 190, 792-4. 
(4) Schlagenhauf, P.; Steffen, R.; Lobel, H.; Johnson, R.; Letz, R.; Tschopp, A.; Vranjes, N.; 
Bergqvist, Y.; Ericsson, O.; Hellgren, U.; Rombo, L.; Mannino, S.; Handschin, J.; 
Sturchler, D. Trop. Med. Int. Health 1996, 1, 485-94. 
(5) Silvey, G. A.; Cady, G. H. J. Am. Chem. Soc. 1950, 72, 3624-6. 
(6) Sipyagin, A. M.; Enshov, V. S.; Kashtanov, S. A.; Bateman, C. P.; Mullen, B. D.; Tan, 
Y.-T.; Thrasher, J. S. J. Fluor. Chem. 2004, 125, 1305-16. 
(7) Tuteja, R. FEBS J. 2007, 274, 4670-9. 
(8) Obiaga, G. O. Am. J. Health. Syst. Pharm. 1998, 55, 1928-31. 
(9) Miller, L. H.; Baruch, D. I.; Marsh, K.; Doumbo, O. K. Nature 2002, 415, 673-9. 
(10) Wallace, D. J. Lupus 1996, 5, S59-S64. 
(11) Chou, A. C.; Fitch, C. D. Biochem. Biophys. Res. Commun. 1993, 195, 422-7. 
(12) AlKadi, H. O. Chemotherapy 2007, 53, 385-91. 
(13) Woodward, R. B.; Doering, W. E. J. Am. Chem. Soc. 1944, 66, 849-849. 
(14) Loeb, R. F. J. Am. Med. Assoc. 1946, 132, 321-3. 
(15) Niles, J. C.; De Risi, J. L.; Marletta, M. A. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 
13266-71, S13266/1-66/4. 
(16) Segal, H. E.; Chinvanthananond, P.; Laixuthai, B.; Pearlman, E. J.; Hall, A. P.; 
Phintuyothin, P.; Na-Nakorn, A.; Castaneda, B. F. Trans. R. Soc. Trop. Med. Hyg. 1975, 
69, 139-42. 
(17) Wang, P.; Brobey, R. K. B.; Horii, T.; Sims, P. F. G.; Hyde, J. E. Mol. Microbiol. 1999, 
32, 1254-62. 
(18) Wongsrichanalai, C.; Pickard, A. L.; Wernsdorfer, W. H.; Meshnick, S. R. Lancet Infect. 
Dis. 2002, 2, 209-18. 
(19) Ohnmacht, C. J.; Patel, A. R.; Lutz, R. E. J. Med. Chem. 1971, 14, 926-8. 
(20) Bami, H. L. Curr. Sci. 1949, 18, 77-77. 
(21) Fidock, D. A.; Nomura, T.; Wellems, T. E. Mol. Pharmacol. 1998, 54, 1140-7. 
(22) Gozal, D.; Hengy, C.; Fadat, G. Antimicrob. Agents Chemother. 1991, 35, 373-6. 
(23) Orlando, R.; Tiseo, D.; Tosone, G.; Cangiano, F.; Scordino, F. Minerva Ginecol. 1990, 
42, 45-7. 
 150 
(24) Li, G. Q.; Guo, X. B.; Jian, H. X.; Fu, L. C.; Shen, L. C.; Li, R. S.; Dai, B. Q.; Li, Z. L. 
Tradit. Chin. Med. 1985, 5, 159-61. 
(25) Hien, T. T. Trans. R. Soc. Trop. Med. Hyg. 1994, 88 Suppl 1, S7-8. 
(26) Rendi-Wagner, P.; Noedl, H.; Wernsdorfer, W. H.; Wiedermann, G.; Mikolasek, A.; 
Kollaritsch, H. Acta Trop. 2002, 81, 167-73. 
(27) Nosten, F.; White, N. J. Am. J. Trop. Med. Hyg. 2007, 77, 181-92. 
(28) Fidock, D. A.; Eastman, R. T.; Ward, S. A.; Meshnick, S. R. Trends Parasitol. 2008, 24, 
537-44. 
(29) Ibezim, E. C.; Odo, U. Afr. J. Biotechnol. 2008, 7, 349-56. 
(30) Price, R.; Luxemburger, C.; Van Vugt, M.; Nosten, F.; Kham, A.; Simpson, J.; 
Looareesuwan, S.; Chongsuphajaisiddhi, T.; White, N. J. Trans. R. Soc. Trop. Med. Hyg. 
1998, 92, 207-11. 
(31) Patarroyo, M. E.; Cifuentes, G.; Bermudez, A.; Patarroyo, M. A. J. Cell. Mol. Med. 2008, 
12, 1915-35. 
(32) Jacobs, G. H.; Aikawa, M.; Milhous, W. K.; Rabbege, J. R. Am. J. Trop. Med. Hyg. 1987, 
36, 9-14. 
(33) Chevli, R.; Fitch, C. D. Antimicrob. Agents Chemother. 1982, 21, 581-6. 
(34) Desneves, J.; Thorn, G.; Berman, A.; Galatis, D.; La Greca, N.; Sinding, J.; Foley, M.; 
Deady, L. W.; Cowman, A. F. Mol. Biochem. Parasitol. 1996, 82, 181-94. 
(35) Stuiver, P. C.; Ligthelm, R. J.; Goud, T. J. Lancet 1989, 2, 282-282. 
(36) Weinke, T.; Trautmann, M.; Held, T.; Weber, G.; Eichenlaub, D.; Fleischer, K.; Kern, 
W.; Pohle, H. D. Am. J. Trop. Med. Hyg. 1991, 45, 86-91. 
(37) Riffkin, C. D.; Chung, R.; Wall, D. M.; Zalcberg, J. R.; Cowman, A. F.; Foley, M.; 
Tilley, L. Biochem. Pharmacol. 1996, 52, 1545-52. 
(38) Cordon-Cardo, C.; O'Brien, J. P.; Casals, D.; Rittman-Grauer, L.; Biedler, J. L.; 
Melamed, M. R.; Bertino, J. R. Proc. Natl. Acad. Sci. U. S. A. 1989, 86, 695-8. 
(39) Aarnoudse, A. L. H. J.; van Schaik, R. H. N.; Dieleman, J.; Molokhia, M.; van 
Riemsdijk, M. M.; Ligthelm, R. J.; Overbosch, D.; van der Heiden, I. P.; Stricker, B. H. 
C. Clin. Pharmacol. Ther. 2006, 80, 367-74. 
(40) Bhattacharjee, A. K.; Karle, J. M. J. Med. Chem. 1996, 39, 4622-9. 
(41) Fletcher, A.; Shepherd, B.; Patent US 6664397. 
(42) Zarantonello, C.; Guerrato, A.; Ugel, E.; Bertani, R.; Benetollo, F.; Milani, R.; Venzo, 
A.; Zaggia, A. J. Fluor. Chem. 2007, 128, 1449-53. 
(43) Bowden, R. D.; Comina, P. J.; Greenhall, M. P.; Kariuki, B. M.; Loveday, A.; Philp, D. 
Tetrahedron 2000, 56, 3399-408. 
(44) Lentz, D.; Seppelt, K. The SF5, SeF5 and TeF5 groups in organic chemistry. In Chemistry 
of Hypervalent Compounds, Akiba, K. (Eds), Wiley-VCH: New York, 1998, 195. 
(45) Andreassen, A. L.; Bauer, S. H. J. Chem. Phys. 1972, 56, 3802-11. 
(46) Sthre, L. J.; Berrah, N.; Bozek, J. D.; Borve, K. J.; Carroll, T. X.; Kukk, E.; Gard, G. L.; 
Winter, R.; Thomas, T. D. J. Am. Chem. Soc. 2001, 123, 10729-37. 
(47) Kiang, T.; Zare, R. N. J. Am. Chem. Soc. 1980, 102, 4024-9. 
(48) Sheppard, W. A. J. Am. Chem. Soc. 1962, 84, 3064-72. 
(49) Hoffmann, F. W.; Simmons, T. C.; Beck, R. B.; Holler, H. V.; Katz, T.; Koshar, R. J.; 
Larsen, E. R.; Mulvaney, J. E.; Rogers, F. E.; Singleton, B.; Sparks, R. S. J. Am. Chem. 
Soc. 1957, 79, 3424-9. 
(50) Loesking, O.; Willner, H. Angew. Chem. Int. Ed. 1989, 101, 1283-4. 
 151 
(51) Brel, V. K. Synthesis 2005, 1245-50. 
(52) Case, J. R.; Ray, N. H.; Roberts, H. L. J. Chem. Soc. 1961, 2066-70. 
(53) Ait-Mohand, S.; Dolbier, W. R. Org. Lett. 2002, 4, 3013-5. 
(54) Sheppard, W. A. J. Am. Chem. Soc. 1962, 84, 3072-6. 
(55) Sipyagin, A. M.; Bateman, C. P.; Tan, Y.-T.; Thrasher, J. S. J. Fluor. Chem. 2001, 112, 
287-95. 
(56) Kirsch, P.; Bremer, M.; Heckmeier, M.; Tarumi, K. Angew. Chem. Int. Ed. 1999, 38, 
1989-92. 
(57) Kirsch, P.; Hahn, A. Eur. J. Org. Chem. 2005, 70, 3095-100. 
(58) Lim, D. S.; Choi, J. S.; Pak, C. S.; Welch, J. T. J. Pestic. Sci. 2007, 32, 255-9. 
(59) Kleemann, H.-W. Patent US 2003/0216476. 
(60) Lutz, R. E.; Ohnmacht, C. J.; Patel, A. R. J. Med. Chem. 1971, 14, 926-8. 
(61) Kumar, M. S.; Nageshwar, Y. D.; Meshram, H. M. Synth. Commun. 1996, 26, 1913-9. 
(62) Adam, S. Tetrahedron 1989, 45, 1409-14. 
(63) Tomooka, K.; Yamamoto, H.; Nakai, T. J. Am. Chem. Soc. 1996, 118, 3317-8. 
(64) Chan, T.-H. Acc. Chem. Res. 1977, 10, 442-8. 
(65) Catala, J. M.; Clouet, G.; Brossas, J. J. Organomet. Chem. 1981, 219, 139-43. 
(66) Pratt, L. M.; Newman, A.; Cyr, J. S.; Johnson, H.; Miles, B.; Lattier, A.; Austin, E.; 
Henderson, S.; Hershey, B.; Lin, M.; Balamraju, Y.; Sammonds, L.; Cheramie, J.; 
Karnes, J.; Hymel, E.; Woodford, B.; Carter, C. J. Org. Chem. 2003, 68, 6387-91. 
(67) Adam, S. Tetrahedron 1991, 47, 7609-14. 
(68)     Carroll, F. I.; Blackwell, J. T. J. Med. Chem. 1974, 17, 210-9.   
(69) Dow, G. S.; Chen, Y.; Andrews, K. T.; Caridha, D.; Gerena, L.; Gettayacamin, M.; 
Johnson, J.; Li, Q.; Melendez, V.; Obaldia, N., III; Tran, T. N.; Kozikowski, A. P. 
Antimicrob. Agents Chemother. 2008, 52, 3467-77. 
(70) Kleemann, H.-W. Patent WO 2006/027130. 
(71) Horwitz, J. P.; Iyer, V. K.; Vardhan, H. B.; Corombos, J.; Brooks, S. C. J. Med. Chem. 
1986, 29, 692-8. 
(72) Kleemann, H.-W.  Patent WO 2006/027129. 
(73) Si, Y.-G.; Neumeyer, J. L. Synthesis 2007, 3787-90. 
(74) Kotsuki, H.; Datta, P. K.; Hayakawa, H.; Suenaga, H. Synthesis 1995, 1348-50. 
(75) Wang, Q.; Rager, J. D.; Weinstein, K.; Kardos, P. S.; Dobson, G. L.; Li, J.; Hidalgo, I. J. 
Int. J. Pharm. 2005, 288, 349-59. 
(76) Kalvass, J. C.; Maurer, T. S. Biopharm. Drug Dispos. 2002, 23, 327-38. 
 
 
 
 
 
